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Abstract 
Despite compelling evidence behind the efficacy of pre-exposure prophylaxis (PrEP) in 
preventing human immunodeficiency virus (HIV) acquisition and its introduction in 2012, the 
prescription of PrEP has remained low (Silapaswan, Krakower, & Mayer, 2016). At the Asian 
and Pacific Islander Wellness Center (API), an urban primary care clinic in San Francisco, 
suboptimal PrEP implementation was related to a lack of standardized practice and routine HIV 
risk screening for PrEP provision. A doctorate of nursing (DNP) project was implemented to 
initiate a standardized HIV risk screening protocol for identifying HIV risk and PrEP eligibility 
to increase PrEP implementation at API. The impact of this protocol demonstrated an increase in 
the PrEP implementation cascade, particularly in HIV risk identification, PrEP offer, and 
evaluation of at-risk patients for PrEP uptake (initiation). During implementation of the HIV risk 
screening protocol, however, inconsistent clinical staff compliance with the routine screening 
tool led to an inadequate increase in PrEP offer for patients who tested positive for a sexually 
transmitted infection (STI). This indicates a need for further reinforcement of standardized 
practice and clinical staff education on the importance of combining HIV risk screening and 
PrEP, with emphasis on the significant risk for HIV infection associated with positive STI, to 
effectively promote patient outcomes. Implications for further research include validation of the 
HIV PrEP screening tool used in the HIV risk screening protocol as a model for PrEP 
implementation in the primary care setting.  
 
Keywords: PrEP implementation, PrEP delivery, PrEP demonstration project, primary 
care, pre-exposure prophylaxis, HIV prevention, HIV risk screening, PrEP screening tool, 
PrEP implementation model 
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Optimizing HIV PrEP Implementation in the Primary Care Setting 
Introduction 
In 2012, the combination antiretroviral drug, tenofovir disoproxil fumarate/emtricitabine 
(TDF/FTC), was federally approved in the United States (US) for use as pre-exposure 
prophylaxis (PrEP) for preventing HIV infection (Centers for Disease Control and Prevention, 
2014). PrEP is the first drug of its kind to prevent HIV acquisition in high-risk populations, 
proven to be up to 92% effective (CDC, 2014). While such evidence is a promising start, the lack 
of widespread dissemination of the literature and practice guidelines limits its impact. Currently, 
there is a need for increased implementation of the evidence, via standardized practice models, in 
primary care settings providing care to at-risk populations (Silapaswan et al., 2016). The Asian 
and Pacific Islander Wellness Center (API), an urban federally qualified health center (FQHC) 
located in an HIV endemic area, provides care for an at-risk patient population that would benefit 
from PrEP. This DNP project proposed to optimize PrEP implementation at API through 
standardization of clinical practice with an emphasis on increasing routine HIV risk screening, 
which can serve as a model applicable to other primary care settings. 
Problem Description 
Although HIV can be managed as a chronic illness in the United States for those who 
have healthcare access and respond to antiretroviral treatment, it remains a serious preventable 
communicable disease. In 2015, 39,513 persons were newly diagnosed with HIV in the United 
States (CDC, 2016). As of June 2016, there are 16,030 people living with HIV in San Francisco 
(San Francisco Department of Public Health, 2016). Because HIV is endemic in San Francisco, 
an independent, volunteer-led, multi-sector consortium called the Getting to Zero San Francisco 
initiative established its mission to achieve UNAIDS’s (United Nations program on HIV/AIDS) 
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vision of zero new HIV infections, zero HIV deaths, and zero HIV stigma by 2020 (Getting to 
Zero San Francisco, 2015) (United Nations program on HIV/AIDS, 2011). 
API is a non-profit, urban primary care clinic in the Tenderloin district of San Francisco 
that serves a disenfranchised patient population, consisting of lesbian, gay, bisexual, transgender 
and queer (LGBTQ), and low-income people of color. As of April 2016, an estimated 61% of 
patients had substantial risk for acquiring HIV due to intravenous drug use, commercial sex 
work, being in an HIV serodiscordant relationship, or inconsistent safe sex practices (T. Do, 
personal communication, February 25, 2016). Prior to this DNP project, API did not have an 
established PrEP implementation protocol or a standardized screening process for HIV risk. 
At API, the following process describes clinic workflow. Per routine, the medical 
assistants (MAs) room the patient, collect vital signs, and perform routine health screenings, such 
as the PHQ-2 and -9, AUDIT-C (Appendix A), and sexual history assessment. The results are 
documented into the electronic health record (EHR) and reported to the nurse practitioners (NPs) 
or physician before they assess the patient. Due to a lack of standardization specifying the health 
screenings associated with the type of patient encounter, health screenings were performed 
inconsistently. For example, the sexual history assessment was conducted for many patient 
encounters but was often missed for straightforward visits, particularly STI testing. Although the 
sexual history assessment screen in the EHR collected important information about sexual risk 
behavior, it did not flag HIV risk. Without appropriate clinical staff training to use the sexual 
history information to assess for HIV risk, the screen was ineffective for identifying at-risk 
patients who qualify for PrEP. 
PrEP implementation consists of the following steps, also known as a “cascade” (B. 
Turner, personal communication, April 6, 2016). The first step is screening for HIV risk per 
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CDC guidelines (Appendix B) (CDC, 2014). Once an at-risk patient is identified, the second step 
is PrEP offer, which involves the provider discussing and offering PrEP as an HIV prevention 
method. After a patient accepts PrEP offer, the third step is PrEP evaluation. Evaluation involves 
laboratory testing and physical examination to confirm that a patient is eligible, in other words 
safe, to start PrEP. The final step in the cascade is PrEP uptake, which is the prescription and 
patient initiation of PrEP.  
It is important to note that PrEP uptake can be limited by the financial cost of TDF/FTC. 
The drug cost of PrEP is approximately $13,000 per patient per year (CDC, 2015). Depending on 
a patient’s health insurance plan, the cost of PrEP may not be fully covered, posing a barrier to 
receiving a prescription for and initiating PrEP. At API, such financial barriers to PrEP are 
resolved by the PrEP case manager, now PrEP navigator, by connecting patients with the Gilead 
Sciences (the pharmaceutical company that manufactures TDF/FTC) financial assistance 
program and copay cards, or Medi-Cal health insurance coverage. Medi-Cal covers the entire 
cost of PrEP (T. Do, personal communication, May 9, 2016).  
Baseline data collected on the clinical practice of PrEP implementation at API 
demonstrated that only 48% of patients with a history of sexual HIV risk, and 35% of patients at 
risk for acquiring HIV due to testing positive for an STI were offered PrEP (Appendices B and 
C). These results revealed a considerable gap between the CDC’s PrEP clinical practice 
guidelines and actual clinical practice (CDC, 2014). The lack of standardized HIV risk screening 
during API’s PrEP implementation is a contributing factor to this gap in practice. This is 
significant because screening is the first step to prevention or treatment.  
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Available Knowledge 
Review of evidence: efficacy of PrEP for HIV prevention. A significant amount of 
peer reviewed, placebo-controlled, randomized controlled trials (RCTs) demonstrate the 
effectiveness of PrEP in preventing at-risk patients from acquiring HIV. The following evidence 
from the World Health Organization (WHO) (2012) and the CDC (2014) suggest a strong impact 
in protection rates against HIV when using PrEP. A literature review was completed to study the 
methodology of PrEP trials and success rates, which summarized the evidence supporting PrEP. 
The literature was retrieved from the provider resources folder located in API’s intranet, and 
from searching the following key words on the CINAHL database: PrEP, pre-exposure 
prophylaxis, HIV prevention. A critique of the reviewed literature was performed using the Johns 
Hopkins Nursing Evidence Based Practice (JHNEBP) Research Evidence Appraisal instrument 
(Appendix D).  
  The WHO (2012) conducted a meta-analysis of eight RCTs using TDF or TDF/FTC for 
PrEP among the following populations and settings: a. heterosexual serodiscordant couples (in 
which one partner is living with HIV) in Kenya and Uganda; b. heterosexual women and men in 
Botswana; c. women at higher risk of contracting HIV in Kenya, South Africa and Tanzania; d. 
men and transgender women who have sex with men from the landmark “iPrEX” study 
conducted in Peru, Ecuador, Brazil, Thailand, South Africa, and the US. TDF/FTC’s 
effectiveness in reducing HIV infection and its relationship with medication adherence were 
analyzed. The result demonstrated 92% effectiveness in preventing HIV infection among 
participants maintaining high medication adherence, as evidenced by their detectable serum 
TDF/FTC level (WHO, 2012). The WHO study involved 14,951 participants. Results validated 
that TDF/FTC for PrEP is 90-92% effective in preventing HIV infection in persons practicing 
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high medication adherence. The CDC (2014) repeated this meta-analysis, also including a RCT 
of 2,411 intravenous drug users (IDUs) in Bangkok, which produced similar results, thus 
confirming PrEP’s effectiveness. The CDC then created the PrEP clinical practice guidelines 
using this data. 
 The WHO (2015) later conducted another meta-analysis of 12 trials, supporting the 
effectiveness of PrEP among serodiscordant couples, heterosexual men and women, men who 
have sex with men (MSM), IDUs, and transgender women. These trials took place in Africa, 
Asia, Europe, South America and the US. These results established that TDF/FTC for PrEP is 
effective in reducing risk for HIV infection with high medication adherence, regardless of age, 
gender, antiretroviral regimen, and mode of sexual transmission (WHO, 2015).  
Additional information on PrEP recommendations. Additionally, the WHO (2015) 
performed a qualitative literature review on administering PrEP to explore the cost-effectiveness, 
equity, and acceptability of PrEP. The financial cost-effectiveness of PrEP varies depending on 
the relative cost of PrEP versus HIV treatment. In terms of the demographic incidence of HIV, 
preventing HIV transmission and keeping persons HIV-negative is invaluable to communities. 
PrEP promotes equitable health outcomes of persons and their sexual partners, as well as access 
to sexual health services during follow-up. Acceptability refers to how much the 
recommendation of PrEP use is accepted by the patients who are affected by it and the healthcare 
providers who can implement it (WHO, 2015). Widespread acceptability was reported across 
multiple at-risk populations. Based on the results of this study, the WHO (2015) updated its 
guidelines and now highly recommends starting PrEP not only for high-risk patients, but also for 
patients with substantial risk for HIV infection per CDC guidelines (Appendix B). Substantial 
risk for HIV infection is defined as meeting at least one of the following criteria in MSM, 
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heterosexual, and IDU populations: HIV-positive sexual or injecting partner; recent bacterial 
STI; high number of sex partners; history of inconsistent or no condom use; commercial sex 
work; located in high-prevalence area or network; sharing injection equipment; and recent 
intravenous drug treatment but currently injecting (CDC, 2014). Therefore, the WHO 
recommends expanding PrEP uptake to a wider patient population. 
Review of evidence: PrEP implemenation. Although significant evidence proves the 
efficacy of PrEP in preventing HIV acquisition, a limited amount of studies demonstrating how 
to best implement PrEP in the primary care setting exists (Scholl, 2015). The literature search for 
this review of evidence was conducted using the CINAHL database by searching the following 
key words: PrEP implementation, PrEP demonstration project, PrEP implementation model, 
HIV risk screening, PrEP screening, primary care, and HIV prevention. The search yielded few 
relevant articles about PrEP implementation, let alone in the primary care setting. No studies of 
models for practicing PrEP implementation specifically in the primary care setting were 
generated. A critique of the reviewed literature was also conducted using the JHNEBP Research 
Evidence Appraisal instrument (Appendix E), confirming that most of the literature consisted of 
qualitative studies identifying barriers to PrEP implementation, and implications for practice 
(Scholl, 2015).  
While no studies of PrEP implementation in the primary care setting were obtainable in 
the literature search, studies performed in STI clinics demonstrate PrEP implementation models 
targeting MSM. At a Rhode Island STD Clinic, PrEP implementation involved offering PrEP 
education for every MSM patient presenting for STI testing, regardless of reported risk factors, 
followed by a brief questionnaire assessing patient interest in PrEP, and a scheduled appointment 
–for those who reported interest –with a provider for PrEP evaluation and initiation (Chan et al., 
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2016). Results across the PrEP implementation cascade reported that 60% expressed interest in 
PrEP after receiving education; of whom 22% completed PrEP evaluation; and 81% of whom 
actually initiated PrEP (Chan et al., 2016). Overall, only 10% of the targeted MSM initiated 
PrEP. The results are primarily related to patients’ low HIV risk perception, indicating the 
importance of emphasizing individual HIV risk factors to increase PrEP implementation. 
 Aiming to assess the feasibility and acceptability of implementing PrEP to MSM and 
transgender women in the STI clinic and community health center setting, the US PrEP 
demonstration project targeted these high-risk populations (Cohen et al., 2015). “The Demo 
Project” implemented PrEP at STI clinics in San Francisco and Miami, and at a community 
health center in Washington, D.C. At the San Francisco STI clinic, providers used the clinic’s 
standardized HIV risk assessment, routinely administered to all MSM & transgender women, to 
identify eligible patients for referral to participate in the study. MSM and transgender women 
who requested PrEP were also referred for study participation –as “self-referrals”–if risk criteria 
were met. In Miami, MSM and transgender women were informed about PrEP and the study. All 
interested patients were referred to the PrEP team for prescreening prior to study participation. 
While at the D.C. community health center, study staff directly approached MSM and 
transgender women seeking HIV and STI screening to offer them the opportunity for 
prescreening and participation in the study. Of the 557 participants enrolled, 60.5% completed 
PrEP uptake. The participants’ demographic factors, behavioral risk characteristics, HIV risk 
perception, and interest in PrEP were analyzed. Results show that PrEP uptake was high across 
demographic factors and clinic sites. This indicated high levels of willingness to take PrEP if 
patients accept its efficacy as an HIV prevention method, and if PrEP is provided at low or no 
cost (Cohen et al., 2015). Although targeting only MSM and transgender women, the 
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standardization of the prescreening intervention proved effective in recruiting participants and 
producing high levels of PrEP uptake. 
Most of the articles published on PrEP implementation models are qualitative studies that 
identify barriers to increasing PrEP uptake (Appendix E). In a study of community FQHCs in 
southeastern Florida, clinical staff perspectives on PrEP implementation were assessed 
(Doblecki-Lewis & Jones 2016). The results were clear, that cultural stigma surrounding HIV 
and sexual risk behaviors; concerns regarding documentation status, health insurance, and 
financial cost; clinical staff knowledge of PrEP, and discomfort with discussing sexual history 
and HIV risk screening contribute to the low implementation of PrEP despite serving high-risk 
patient populations.  
There is low PrEP implementation nationwide according to the narrative review 
conducted by Silapaswan et al. (2016). Only a minority of at-risk persons who could benefit 
from PrEP is taking it due to a limited number of healthcare practitioners trained to provide 
PrEP. Addressing this barrier requires increased patient access to PrEP. Therefore, the authors 
suggest that primary care practitioners should be the primary providers of PrEP because it is a 
preventative health intervention for otherwise healthy individuals. 
However, there are conflicting perspectives among healthcare providers regarding who is 
best fit to provide PrEP and which healthcare setting is most appropriate for PrEP 
implementation (Hoffman et al., 2016). For example, Hoover, Ham, Peters, Smith and Bernstein 
(2016) suggest that PrEP is best implemented in STI clinics because of the shared sexual risk 
behaviors related to acquiring HIV and other STIs, and persons infected with a bacterial STI are 
more susceptible to HIV infection. Furthermore, STI clinics disproportionately provide services 
for high-risk patient populations. Some primary care providers reported preference for HIV 
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specialists, who are experts on antiretroviral therapy and HIV transmission, to serve as PrEP 
providers (Hoffman et al., 2016). Meanwhile, some HIV specialists argue that HIV-negative 
patients are not going to seek their services. Therefore, the wide net for health screenings cast in 
the primary care setting supports that primary care providers are uniquely qualified for 
prescribing PrEP (Hoffman et al., 2016). The lack of a unanimous stance on where PrEP belongs 
in healthcare poses a significant barrier to its widespread dissemination. Further research using 
implementation science is needed to determine the most effective setting for PrEP 
implementation (Hoffman et al., 2016).  
Although it is currently unclear which healthcare setting–STI clinics, community health 
centers, HIV specialists, or primary care – is most appropriate for providing PrEP, the qualitative 
studies in this review of evidence offer implications for practice to address barriers to PrEP 
implementation. According to Doblecki-Lewis, and Jones (2016), Silapaswan et al. (2016), and 
Hoffman et al. (2016), increasing provider knowledge of PrEP is the most common 
recommendation across qualitative studies. Raifman, Flynn, and German (2016) identify that 
provider knowledge is especially important as patient awareness of PrEP was found to be 
unassociated with most healthcare contact. Training and guidelines are needed to support 
provider discussion with patients about sexual history and PrEP. Furthermore, improved methods 
for identifying at-risk patients who qualify for PrEP via routine sexual history/gender identity 
questions are recommended to optimize PrEP implementation in the primary care setting 
(Silapaswan et al., 2016).  
Additional information on HIV risk screening in primary care. Because PrEP is a 
preventative intervention that requires prescreening, it should be considered similar to other 
preventative health services (Silapaswan et al., 2016). As with all routine screenings that are 
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offered in primary care, such as AUDIT-C for alcohol dependence and PHQ-2 and -9 for 
depression and suicide (Appendix A), HIV risk screening for PrEP implementation can also be 
provided in this setting (Smith, Pals, Herbst, Shinde, & Carey, 2012).  
In 2006, the CDC recommended the expansion of HIV screening to non-targeted (“opt-
out”) routine HIV testing in all healthcare settings in the US (Haukoos et al., 2011). However, 
non-targeted HIV testing was not widely adopted in clinical practice, especially in primary care, 
because such large-scale screening is not cost-efficient (Haukoos et al., 2011). In 2007, the US 
Preventative Services Task Force (USPSTF) recommended targeted (among high-risk 
populations) HIV screening as the primary method of HIV testing (Haukoos et al., 2011). As a 
compromise between the conflicting recommendations, the Denver HIV risk score, derived from 
targeted HIV screening, was internally and externally validated by Haukoos et al. (2011). The 
results of the study confirmed efficacious applicability of this HIV risk assessment tool across 
healthcare settings, including non-targeted settings such as primary care.  
The most current USPSTF recommendation for routine HIV screening in the primary care 
setting states that one-time testing for HIV infection can begin at age 15 through age 65 with 
repeat testing for those identified as at risk for HIV infection, engaged in risky behaviors, and 
who live or receive medical care in a high-prevalence setting (US Preventative Services Task 
Force, 2013). Because there is insufficient evidence to determine standard HIV testing intervals, 
a reasonable approach is to screen high-risk groups at least annually, and at-risk groups every 3-5 
years (USPSTF, 2013). However, there is no recommendation for HIV risk screening. HIV risk 
screening in primary care can determine appropriate HIV testing intervals for individuals based 
on identified HIV risk factors, as supported by the results of the Denver HIV risk score study 
(Haukoos et al., 2011). Therefore, the Denver HIV risk score study supports the feasibility of 
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increasing PrEP implementation in primary care through HIV risk screening. As preventative 
health is one of the tenants of primary care, and the first step in prevention is screening, primary 
care is the appropriate setting for routine HIV risk screening and PrEP implementation.  
Smith et al. (2012) developed and validated a screening tool for identifying high-risk 
MSM, for whom PrEP is appropriate, called the HIV Incidence Risk Index for MSM (HIRI-
MSM). The index included the following seven items: a. age; b. number of sex partners in the 
past six months; c. number of times receptive anal intercourse performed in past six months; d. 
number of HIV-positive sex partners; e. number of times insertive anal intercourse performed; f. 
number of times methamphetamines used in the past six months; g. use of “poppers” in the past 
six months? A cut-off score of 10 was found to be predictive of HIV acquisition with a 
sensitivity of 84% and a specificity of 45%. Although the HIRI-MSM is a valid screening tool 
targeting only MSM, the study of the index suggests widespread use for prioritizing at-risk 
patients for PrEP (Smith et al., 2012). Therefore, expansion of an MSM-targeted screening tool 
to other at-risk populations represents a model by which PrEP implementation in the primary 
care setting can be increased. 
Rationale 
The core of this DNP project consisted of changing API’s PrEP implementation practice 
by developing and implementing an HIV risk screening protocol by educating clinical staff, 
employing an HIV PrEP screening tool, and integrating the change into routine clinical practice. 
One theoretical framework used in the development of this project is the Diffusion of Innovation 
Theory popularized by Everett Rogers (Kaminski, 2011). This theory represents the process that 
occurs as people adopt a new practice. Over time, the innovative practice is diffused amongst the 
population until a saturation point is reached, and the majority adopts the new practice as status 
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quo. This theory is applicable to innovations in healthcare and health informatics (Angeles, 
Dolovich, Kaczorowski & Thabane, 2014). The HIV risk screening protocol will diffuse among 
the clinical staff at API, and has the potential to be adopted by other primary care clinics in San 
Francisco if this DNP project’s model for PrEP implementation is disseminated.  
 The Awareness to Adherence Model, which states that provider compliance with clinical 
practice guidelines is dependent upon the following steps: awareness, agreement, adoption, and 
adherence (Freed, Pathman, Konrad, Freeman, & Clark, 1998). This model well describes the 
way in which this project will bring awareness of the CDC (2014) PrEP clinical practice 
guidelines through educating and training API providers and clinical staff on HIV risk 
identification and following the HIV risk screening protocol. The API providers and clinical staff 
will agree to follow the new HIV risk screening protocol after understanding its rationale and 
benefits to their patient population. Adoption of the HIV risk screening protocol into routine 
clinical practice should be effective due to API’s small size and few organizational barriers. The 
author will be available to reinforce routine screening tool use to achieve adherence.  
Specific Aims 
The aim of this DNP project was to improve HIV prevention in a primary care setting 
over a period of six months by increasing clinical staff identification of patients with substantial 
risk for HIV, per CDC guidelines, through the implementation of a standardized HIV risk 
screening protocol, as evidenced by increasing PrEP offer and evaluation for initiating TDF/FTC 
for PrEP by 50% (Appendix F). The goal is to optimize HIV prevention at primary care clinics in 
order to contribute to the Getting to Zero San Francisco initiative.  
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Methods 
Interventions 
The primary intervention employed to change current practice and improve PrEP 
implementation at API is the development of a standardized HIV risk screening protocol that 
uses an HIV PrEP screening tool in the EHR. This will be accomplished by educating clinical 
staff to routinely identify patients at risk for acquiring HIV who should be offered PrEP. The 
HIV PrEP screening tool integrates the sexual history assessment with HIV risk screening to 
streamline clinical practice. The following objectives describe the methods of the HIV risk 
screening protocol:  
1. Establish a standardized screening process: as patients are roomed, the MAs use the HIV 
PrEP screening tool to assess for HIV risk and qualification for PrEP offer for each 
establish new patient, STI testing, and annual physical exam patient encounter, and report 
results to the providers.   
2. Educate all clinical staff on routine HIV risk identification, per CDC criteria, using the 
HIV PrEP screening tool and the new screening process. 
3. Develop a standardized HIV PrEP screening tool and integrate it into the EHR (Appendix 
G) to assist clinical staff in increasing identification of patients at substantial risk for HIV 
acquisition, and subsequently increase PrEP offer and evaluation. 
4. Develop clinical decision support tools in the EHR (Appendix H) to supplement the 
optimization of PrEP implementation: a PrEP evaluation order set linked to ICD-10 
diagnostic codes related to STI screening and treatment, and a PrEP evaluation progress 
note template. The PrEP evaluation order set triggers providers to implement PrEP and 
decreases EHR related burden for ordering evaluation and follow-up, and it includes a 
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link to provider guidelines and patient education materials. The PrEP evaluation progress 
note template streamlines and standardizes the documentation of PrEP evaluation.  
5. Educate providers on accessing the PrEP clinical decision support tools. 
6. Evaluate clinical staff comprehension with post-education tests (Appendix I). 
7. Launch the HIV risk screening protocol for clinical practice at API. 
8. Reinforce change by following up with clinical staff on HIV risk screening protocol 
compliance –the routine utilization of the HIV PrEP screening tool per the established 
screening process. 
Gap analysis. Prior to initiating this DNP project, a gap analysis (Appendix J) of API’s 
clinical practice of PrEP implementation was conducted through observation of clinical practice 
and a baseline clinical data assessment (Appendix C). Based on observations of clinical practice, 
a lack of standardization specifying the health screenings to be conducted for the type of patient 
encounter was noted. Consequently, the sexual history assessment was performed inconsistently. 
Furthermore, the sexual history assessment screen did not identify HIV risk despite the relevant 
information it collected. Without appropriate clinical staff training to use sexual history 
information to assess for HIV risk, the screen was ineffective for identifying at-risk patients who 
should be offered PrEP. Additionally, differences in provider preference on which clinical staff 
conducted health screenings (providers themselves or the MAs), and the high rate of clinical staff 
turnover further contributed to inconsistencies in practice.  
The baseline clinical data assessment was conducted by collecting and analyzing clinical 
data from December 7, 2015 through April 8, 2016. Patient lists were generated from the 
following data categories: STI treatment medications ordered, ICD-10 code Z11.3 (encounter for 
screening for infections with a predominantly sexual mode of transmission), and STI lab tests 
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ordered. The author performed individual patient chart reviews to identify those who qualified 
for PrEP based on testing positive for an STI or sexual HIV risk (per CDC guidelines), and if 
they were offered PrEP. The data analysis yielded the following gaps in identifying and offering 
PrEP to patients with substantial risk for acquiring HIV per CDC guidelines. Of the patients with 
a history of sexual HIV risk, 48% were offered PrEP (Appendix C). Of those who tested positive 
for an STI, 35% were offered PrEP. Therefore, a significant gap exists between the number of at-
risk patients who qualify for PrEP and the number of these patients who were actually offered 
PrEP. According to this gap analysis, it was determined that API’s PrEP implementation 
guidelines could benefit from a change in practice through this DNP project.  
Gantt narrative. This DNP project timeline took place from March 2016 to February 
2017 (Appendix K). In March 2016, the author visited API and spoke to Dr. Tri Do, the chief 
medical officer (CMO), about the clinic’s needs. By the end of April 2016, the author selected 
the DNP project topic after researching evidence-based literature on PrEP and conducting a gap 
analysis of API’s PrEP implementation practice. June through September 2016 was spent 
designing the HIV risk screening protocol –the implementation of an electronic screening tool 
into clinical practice. The development of the HIV PrEP screening tool, the first critical 
milestone, and the additional PrEP clinical decision support tools were completed in September 
2016. The second milestone, clinical staff education was delayed by one month due to 
scheduling conflicts, and was instead completed in October 2016. Subsequently, the HIV PrEP 
screening protocol was launched on November 1, 2016, postponing the third milestone by one 
month. The fourth and final milestone, evaluation of the intervention and its measurable 
outcomes, started in January 2017 and was completed in February 2017.  
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SWOT analysis. The following SWOT analysis describes API’s strengths, weaknesses, 
opportunities, and threats that have the potential to affect the implementation of this DNP project 
(Appendix L). 
Strengths. API’s compassionate and culturally sensitive environment, its small 
organizational size, FQHC status, and its specific patient population (LGBTQ and low-income 
people of color) represent strengths. Because both the patient population and API staff share 
similar backgrounds as LGBTQ community members and/or people of color, the culture at API 
produces a trusting environment that is open to change for improvement. Since it is a small 
organization, there is minimal bureaucratic pushback. Rather, the author receives support, such 
as access to invaluable resources, from Dr. Blair Turner, the lead NP who supervised this DNP 
project, and Dr. Do, the CMO/physician. FQHC status also contributes to API’s strengths 
because federal funding reduces financial limitations to providing care. Furthermore, API’s 
patients represent the at-risk population that qualifies for PrEP. Therefore, this DNP project is 
appropriate and relevant. These strengths promote this DNP project’s capability to improve the 
clinic’s PrEP implementation. 
Weaknesses. The small size of API, high clinical staff turnover rate, and the outdated 
EHR system represent weaknesses. Although API’s small organizational size is a strength 
because it produces less resistance to change, its small size as a free-standing clinic also 
represents a weakness. Since the clinic is not part of a larger health care system, it had few 
standardized protocols and policies. During protocol development there were constant workflow 
changes, resulting in difficulty establishing new protocol into routine. Additionally, the clinical 
staff turnover rate is high because nurses and MAs are often volunteers or hired temporarily from 
an agency, so new staff are constantly being trained. API’s EHR system represents another 
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weakness because it is inefficient and has limited ability to capture clinical data. Difficulty 
navigating the EHR was expected to pose problems in this DNP project during the baseline 
assessment and evaluation. Therefore, project implementation was expected to face difficulties 
with technology and adherence to change in practice.  
Opportunities. The FQHC status API received in December 2015 creates the opportunity 
to provide preventative care to more patients, and potentially meet the federally required EHR 
meaningful use standards of promoting patient health outcomes (C. Ong-Flaherty, April 7, 2016). 
FQHC status opens the clinic’s doors to more patients in the community, which represents an 
opportunity to optimize HIV prevention efforts through PrEP implementation. Because the 
patient population is at risk for acquiring HIV, this DNP project also has the opportunity to 
produce potentially significant implications in public health by reducing HIV transmission and 
improving patient outcomes in the community, which contribute to the Getting to Zero San 
Francisco initiative. Patient health outcomes currently measured by EHR meaningful use 
standards include scheduled immunizations, and flu and pneumonia vaccinations; and in acute 
care for example, sepsis and heart failure (C. Ong-Flaherty, April 7, 2016). HIV prevention, 
however, has not yet been established as a patient health outcome for meaningful use. If 
established as a measurable outcome in the future, this DNP project can potentially help API 
contribute to its meaningful use of the EHR by using an electronic HIV PrEP screening tool.  
Threats. Patient refusal of PrEP due to cultural stigma, financial cost, and low HIV risk 
perception represent threats. One of the barriers to PrEP uptake is cultural stigma. This cultural 
stigma stems from pre-existing stigma around HIV, but specifically depicts patients taking PrEP 
as “Truvada whores” (Calabrese & Underhill, 2015). Another barrier to PrEP uptake is financial 
cost. While some health insurance plans, such as Medi-Cal, cover the entire cost of PrEP, others 
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do not (T. Do, personal communication, May 9, 2016). Although API has a PrEP navigator to 
connect patients with financial access to PrEP, the process of acquiring financial resources still 
delays PrEP uptake. During this time waiting for financial coverage for PrEP, patients may 
change their minds or not return to care. Low HIV risk perception is the main reason MSMs at a 
Rhode Island STI clinic declined PrEP, representing an individual-level barrier to PrEP uptake 
(Chan et al., 2016). For these reasons an identified at-risk patient may refuse PrEP evaluation, 
and an eligible patient may refuse to initiate PrEP. Such threats may affect the PrEP 
implementation cascade, and subsequently, this DNP project’s measurable outcomes. 
Cost/benefit analysis. Because of API’s limited budget, this DNP project was created to 
be without financial cost to API by utilizing available resources within the organization. API’s 
full time equivalent (FTE) budget was not available to the author, so estimated costs are based on 
equivalent San Francisco Department of Public Health job wages for each staff member’s hourly 
wage. The estimated cost of this DNP project is $2,156.54, which consists of approximate FTE 
employee hours spent by the following API staff members in project implementation: the CMO, 
lead NP, volunteer NP, MAs, clinical data specialist, EHR system consultant, PrEP case 
manager, clinical operations manager, and director of nursing (Appendix M). The author 
absorbed the majority of this DNP project’s cost as an unpaid resource responsible for project 
development and management. Therefore, project costs were absorbed into API’s FTE budget. 
For other primary care clinics looking to adopt the HIV risk screening protocol, the cost 
would primarily consist of FTE employee hours spent during clinical staff education, a project 
manager to lead the implementation of the protocol, and potential information technology 
assistance for integration into the EHR system. Based on Glassdoor’s database of salary reports, 
the average hourly wage for a project manager consultant is approximately $42.52 (Glassdoor, 
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2017). Including staff FTEs, as estimated above, and the cost to hire a project manager, the total 
estimated cost for a primary care clinic to implement the HIV risk screening protocol is 
$6,408.54 (Appendix M). 
 By preventing HIV infection, this DNP project produces a significant benefit of cost-
avoidance of HIV management (Appendix M). HIV antiretroviral treatment costs approximately 
$20,000 upwards per patient per year (CDC, 2015). The medication cost of PrEP is $13,000 per 
patient per year. If all of API’s suspected at-risk patients (232) acquired HIV and required HIV 
antiretroviral treatment, the estimated minimal cost of treatment is $4,640,000 per year. If started 
on PrEP and HIV infection is prevented instead, the estimated cost is $3,016,000 per year. This 
represents a potential cost avoidance of an estimated $1,624,000 per year.  
By expanding PrEP implementation, this DNP project also produces a return on 
investment (ROI) unique to the API clinic in the form of increased health insurance 
reimbursements. Under its new FQHC status, API qualifies for Medi-Cal reimbursement at the 
rate of $25 per patient per month for total cost of care (T. Do, personal communication, May 9, 
2016). Based on the total estimated at-risk patients (232), assuming they are new to care and 
Medi-Cal coverage, and are started on PrEP, API can potentially receive an estimated 
reimbursement of $69,600 in one year (232 patients x $25 x 12 months per year) at this 
reimbursement rate (Appendix N). This does not account for new Medi-Cal patients as API 
continues to expand, nor future reimbursements from other health insurance plans as new 
contracts are established. Thus, the estimated ROI is conservative and is promising for a new 
FQHC clinic. It is important to clarify that initiating PrEP for established Medi-Cal patients does 
not create additional reimbursement. However, PrEP care does require frequent follow-up, which 
would keep patients in care, contributing to patient, and thus reimbursement, retention. 
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Responsibility/communication plan. The planning involved in this DNP project 
required extensive interdisciplinary responsibility and continuous communication (see Appendix 
O for work breakdown and Appendix P for communication plan). Inter-professional 
collaboration for this project occurred primarily between the author, Dr. Turner and clinical staff, 
and the author’s DNP committee. Working directly with Dr. Turner, the author was responsible 
for the development, management, implementation, and evaluation of the project. Dr. Turner and 
Dr. Do provided assistance, serving as clinical experts of API’s patient population and HIV 
prevention. As API’s lead NP and CMO, they provided authorization for this DNP project and 
changes to clinical practice on site (see letter of support in Appendix Q). The clinical data 
specialist assisted the author with retrieving data from the EHR, while the University of San 
Francisco (USF) health informatics student intern provided assistance with data analysis, for the 
baseline clinical data assessment. To assist the author with the cost/benefit analysis, the clinical 
data specialist reported the approximate patient census for 2016. The API PrEP case manager, 
whose role is to support PrEP patients and conduct outreach to introduce PrEP to the community, 
provided invaluable advice for the appropriate approach to screening patients for HIV risk and 
offering them PrEP. The clinical staff were educated and trained on the HIV risk screening 
protocol. As the lead NP, Dr. Turner was considerably involved in this DNP project by providing 
supervision, developing the HIV risk screening protocol with the author, and educating the other 
providers.  
Additionally, collaboration with the City Wide PrEP NP, who works for the San 
Francisco Department of Public Health to assist primary care clinics in San Francisco with their 
PrEP implementation needs through education and training, was planned for educating API’s 
clinical staff. The following PrEP experts were also interviewed to research local PrEP 
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implementation models during the design of the HIV risk screening protocol: the Gilead 
Sciences assistant director of medical sciences for the west coast region, and local representative; 
and the PrEP program managers at San Francisco City Clinic and Strut. 
Study of the Intervention 
After launching the HIV risk screening protocol, methods for assessing the effectiveness 
of implementation and success of the HIV risk screening protocol were performed (Appendix R). 
First, the clinical staff post-education test scores were evaluated. Not only did the tests assess the 
clinical staff’s comprehension of the HIV risk screening protocol, HIV risk identification and 
PrEP offer; they assessed the effectiveness of the educational training. Next, the author collected 
three months of post-intervention clinical data from the EHR, starting from the launch date of the 
HIV risk screening protocol on November 1, 2016 through February 1, 2017. Analysis of clinical 
data from relevant patient encounters (STI testing, establish new patient, and annual physical 
exam) evaluated staff compliance with the routine utilization of the HIV PrEP screening tool per 
the established screening process. The author further analyzed the data for appropriate 
completion of the PrEP implementation cascade to assess the effect of the HIV risk screening 
protocol on improving API’s clinical practice of PrEP implementation. 
Measures 
Primary outcomes. The following primary outcomes were used to assess the 
effectiveness of the HIV risk screening protocol based on improvement from baseline clinical 
practice, as evidenced by an increase by 50% across the PrEP implementation cascade: 
1. To increase PrEP offer to 72% of patients with sexual HIV risk, compared to the 
baseline of 48% of patients with sexual HIV risk that were offered PrEP. 
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2. To increase PrEP offer to 53% of patients tested positive for an STI, compared to the 
baseline of 35% of patients tested positive for an STI that were offered PrEP. 
3. To increase PrEP evaluation to 53% of patients offered PrEP, compared to the 
baseline of 35% of patients offered PrEP that completed evaluation. 
4. To increase PrEP uptake to 42% of patients evaluated and eligible for PrEP, 
compared to the baseline of 28% of PrEP eligible patients that were prescribed 
TDF/FTC.  
Secondary outcomes. The following secondary outcomes were used to assess the 
effectiveness of implementing the HIV risk screening protocol:  
1. To achieve effective clinical staff educational training as evidenced by post-education 
test scores of 80%.  
2. To achieve adequate clinical staff compliance with using the HIV PrEP screening tool as 
evidenced by a screening rate of 80% for each STI testing, establish new patient, and 
annual physical exam patient encounter.  
Maximizing internal and external validity. In order to maximize internal and external 
validity, the percentage of identified at-risk patients offered PrEP, the percentage of patients 
offered PrEP who completed PrEP evaluation, and the percentage of patients evaluated and 
eligible for PrEP who completed PrEP uptake were calculated and analyzed. Comparing these 
baseline and post-intervention percentages more accurately reflects the effect of the HIV risk 
screening protocol on the PrEP implementation cascade. Because the HIV PrEP screening tool 
asks similar questions as the internally validated Denver HIV risk score, it can be inferred that it 
is also a valid tool for identifying HIV risk (Haukoos et al., 2011). Unlike the Denver HIV risk 
score, the HIV PrEP screening tool does not produce a numerical score to detect HIV risk. 
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Therefore, statistical testing is needed to confirm the validity of the HIV PrEP screening tool. As 
the HIV PrEP screening tool asks questions specific to HIV risk criteria, it represents a reliable 
tool for identifying patients at risk for acquiring HIV. 
External validity of the HIV PrEP screening tool was maximized by incorporating HIV 
risk and PrEP screening with sexual history assessment into one standardized screening tool. The 
HIV PrEP screening tool is applicable to other primary care clinics in San Francisco because 
sexual history assessments are conducted routinely in primary care, as should HIV risk screening 
in San Francisco where HIV is endemic (SFDPH, 2016). Therefore, streamlining both processes 
maximizes the HIV PrEP screening tool’s external validity. As previously mentioned, the HIV 
PrEP screening tool asks similar questions as the Denver HIV risk score, which was also 
externally validated, inferring the external validity of the screening tool (Haukoos et al., 2011). 
Therefore, the HIV PrEP screening tool can be employed across patient populations and 
healthcare settings in the US. However, statistical testing is needed to confirm the tool’s external 
validity. 
Instruments for assessment. The instruments used to assess the effectiveness of the HIV 
risk screening protocol were API’s EHR system and Microsoft Excel (Appendix R). Because the 
HIV PrEP screening tool was implemented and pertinent clinical data is documented into the 
EHR system, the use of the EHR was required for the collection of clinical data analyzed for 
evaluation. Microsoft Excel was used to perform the data analysis to assess intervention 
effectiveness by calculating percentages and creating graphs to compare baseline and post-
intervention results (Appendix S). 
Assuring validity of assessment instruments. Microsoft Excel is a valid instrument 
because it is a data-analyzing software program that functions independently of API’s EHR 
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system. Potential data entry error in Excel was addressed by re-checking electronically entered 
totals multiple times for calculating pertinent values. However, human error in counting numbers 
and entering data in Excel was still possible. The EHR has insufficient validity because of its 
inconsistencies in retrieving clinical data. Meticulous clinical data collection was conducted to 
assure data quality and accuracy. To ensure as complete a set of data as possible, multiple data 
searches were performed, in line with the clinical data specialist’s instructions during the 
baseline clinical data assessment, which generated patient lists from the following search 
categories: STI testing, establish new patient and annual physical exam patient encounters, and 
STI lab orders. From each list, the author performed individual patient chart reviews to identify 
at-risk patients who qualify for PrEP, per CDC guidelines, and if PrEP offer, evaluation and 
uptake were completed. To maintain consistency in data analysis method, duplications were 
managed and deleted, and patients previously started on PrEP or living with HIV were excluded 
from the sample, as performed in the baseline clinical data assessment.  
Analysis 
Only quantitative analytical methods were used in the evaluation of this DNP project, for 
which quantified measurable outcomes were developed. Microsoft Excel, a long-standing 
software program widely used in accounting, statistics, and sciences, was the software used to 
analyze both the baseline and post-intervention clinical data. Through Excel, the results for each 
measure were calculated as percentages, for which graphs were generated. Graphs comparing 
baseline and post-intervention results revealed the effects of the HIV risk screening protocol 
(Appendix S). While graphs displaying the clinical staff post-education test scores and HIV PrEP 
screening tool compliance rates demonstrated the effectiveness of implementing the HIV risk 
screening protocol. 
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Ethical Considerations 
Ethical considerations directly involved in the author’s DNP project implementation and 
evaluation include patient privacy and potential conflict of interest. Patient privacy was protected 
by strict adherence to the Health Insurance Portability and Accountability Act (HIPAA). While 
this project was not research, per Institutional Review Board (IRB) guidelines, a waiver was filed 
(Appendix F). The capture of clinical data from the EHR was conducted only at API within a 
secure network. Patient names and personal information were excluded during the analysis of 
clinical data for evaluation of the intervention. The author reports no personal or financial 
conflicts of interest because her work is unpaid, and she is not affiliated with the pharmaceutical 
company that manufactures TDF/FTC, public health departments, research or other HIV and 
PrEP related organizations.   
Implications for the ethical practice of PrEP implementation in primary care are 
recognized by this DNP project. In accordance with the American Nurses Association Ethical 
Standards and the Jesuit values of the University of San Francisco, the responsibilities of the 
clinician and the healthcare site were examined. Providers must educate patients and weigh the 
risks versus benefits of taking PrEP to practice beneficence and non-maleficence (Rowniak & 
Portillo, 2013). To practice justice, providers must also serve as diligent patient advocates by 
connecting disenfranchised, at-risk patients to social services necessary to access PrEP. 
Furthermore, providers must fulfill their role as fiduciary stewards, and consider the financial 
impact on the healthcare system and society while deciding whether to provide PrEP to a patient 
(Atherton, Blodgett & Atherton, 2011) (Buck, 2016). Despite well-intentioned attempts, 
providers must accept that their efforts to provide the best HIV prevention methods may still be 
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blocked by forces outside of their control, such as patient autonomy and limited access to 
necessary resources (Rowniak & Portillo, 2013). 
Results 
Primary Outcomes 
Comparing baseline and post-intervention clinical data evaluated the effectiveness of the 
HIV risk screening protocol (Appendix S). An increase by 50% from baseline was the 
established target across the PrEP implementation cascade. The results demonstrated positive 
effects: 
1. At baseline, 48% of patients with sexual HIV risk were offered PrEP. After 
implementation of the HIV risk screening protocol, 81% of at-risk patients were offered 
PrEP, exceeding the target goal of 72%. 
2. At baseline, only 35% of patients who tested positive for an STI were offered PrEP. At 
post-intervention, 56% of these patients were offered PrEP, surpassing the target 
percentage of 53%.  
3. At baseline, 35% of patients who were offered PrEP completed PrEP evaluation. After 
project implementation, 56% of these patients were evaluated for PrEP initiation, also 
exceeding the target percentage of 53%. 
4. At baseline, PrEP uptake for patients evaluated and eligible for PrEP was noted at 28%. 
The post-intervention rate of 36% demonstrated an increase, but did not meet the target 
goal of 42%.  
Secondary Outcomes 
 The following secondary outcomes assessed the effectiveness of the implementation of 
the HIV risk screening protocol (Appendix T). 
HIV PREP   33 
 
1. Adequate clinical staff comprehension and effective educational training as evidenced by 
post-education test scores of 80%: Both of the two MAs and one of the two providers 
completed their respective post-tests. The MAs’ test scores were 94% and 56%, 
averaging 75%. The provider scored 75%.  
2. Adequate clinical staff compliance with screening tool use as evidenced by a compliance 
rate of 80% for each of the following patient encounters:  
a. STI testing: 53% (n = 26) 
b. Establish new patient: 74% (n = 62) 
c. Annual physical exam: 100% (n = 1)  
Discussion 
Summary  
Although the outcomes for PrEP offer and evaluation exceeded their respective target 
percentages, the exact percentage targets for PrEP uptake and the secondary outcomes were not 
met. Nonetheless, the aim to increase clinical staff identification of patients with substantial risk 
for acquiring HIV, and subsequent increase in PrEP offer and evaluation for PrEP initiation were 
still achieved. Project evaluation highlighted the importance of communication and reinforcing 
change for effective improvement of clinical practice as targeted. Streamlining the sexual history 
assessment and HIV risk screening into one standardized screening tool proved successful in 
improving the clinical practice of PrEP implementation at API, as evidenced by increased 
percentages across the PrEP implementation cascade. By sharing the HIV risk screening protocol 
with the City Wide PrEP NP, the PrEP implementation model demonstrated by this DNP project 
can be used by other primary care clinics in San Francisco. For clinics with limited EHR 
capacities, the HIV PrEP screening tool can be converted into paper format. Ample clinical staff 
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education and instruction on establishing a standardized screening process is essential for 
effective optimization of PrEP implementation.  
Interpretation and Limitations 
The HIV risk screening protocol produced improvement across primary outcomes, 
exceeding the target percentage of increase except for PrEP uptake (Appendix S). This is related 
to pending health insurance coverage limiting PrEP uptake. If these patients had health insurance 
coverage and received their prescriptions, 100% of those who cleared evaluation would have 
completed PrEP uptake. Specifically measuring improvement in the gap in PrEP implementation 
for patients who tested positive for an STI is an especially important clinical outcome. Although 
PrEP offer increased by 60%, PrEP uptake for patients who tested positive for an STI did not 
improve from baseline because patients declined PrEP initiation (Appendix U), indicating the 
need for extensive and continuous patient discussions about PrEP. Often left unaddressed in 
baseline clinical practice, testing positive for an STI indicates HIV risk. Previous studies have 
shown that MSM in San Francisco who are diagnosed with rectal gonorrhea or chlamydia more 
than once within two years are eight times as likely to acquire HIV; and in Florida, women with 
syphilis were at the highest risk for subsequent diagnosis of HIV infection (Hoover et al., 2016). 
As 56% of patients tested positive for an STI were offered PrEP, and the HIV PrEP screening 
tool was used in 53% of STI testing patient encounters at post-intervention, reinforcement of 
HIV risk screening protocol compliance is warranted to promote patient outcomes. 
The results of the secondary outcomes also demonstrated unmet target percentages. 
Because the average score for both MAs and the one provider who completed their post-
education tests was 75%, as opposed to the target score of 80% each, the effectiveness of the 
clinical staff education was inadequate. This is related to limited time for clinical staff education, 
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and a scheduling conflict that prevented the City Wide PrEP NP from providing education as 
initially planned. A clinical staff compliance rate of 80% for screening tool use in STI testing 
(53%) and establish new patient (74%) encounters was not met (Appendix T). Although the 
annual physical exam patient encounter received a 100% clinical staff compliance rate, there was 
only one documented case over the course of the post-intervention period (n = 1). Therefore this 
result is unreliable. These unmet outcomes demonstrate the unsatisfactory effectiveness of 
implementing the HIV risk screening protocol. Furthermore, API recently established additional 
protocols to meet FQHC standards. Multiple changes in practice and the high rate of clinical staff 
turnover, requiring frequent new employee training, resulted in clinical staff not following the 
HIV risk screening protocol and the subsequent inadequate compliance rate for using the HIV 
PrEP screening tool. Better clinical staff education, communication, and HIV risk screening 
protocol reinforcement could have prevented the inadequate results of the secondary outcomes. 
Additionally, the percentages of patients with substantial HIV risk at baseline (61%) and 
post-intervention (38%) were calculated and compared to address potential changes to the patient 
population and provide context for the results of the primary outcomes (Appendix V). The noted 
difference in the percentage of patients with substantial HIV risk indicates a lower-risk patient 
population for acquiring HIV at post-intervention. The decrease in at-risk patients consequently 
affects the number of patients who qualify for PrEP offer, and subsequently evaluation and 
uptake. The internal validity of this DNP project may have been compromised by this decrease in 
the patient population’s HIV risk.  
It is necessary to reiterate the limitations within API’s EHR system, namely the 
inconsistencies in its capacity to retrieve clinical data. Despite the aforementioned measures to 
assure internal validity, technological limitations may still have affected both baseline and post-
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intervention clinical data collection, and thus evaluation results. Although not all target outcomes 
were met, the HIV risk screening protocol can still be a viable model for increasing PrEP 
implementation in primary care, as supported by the studies of the Denver HIV risk score and 
HIRI-MSM (Haukoos et al., 2011) (Smith et al., 2012).  
Conclusions 
 The HIV risk screening protocol produced improvement in API’s clinical practice of 
PrEP implementation by increasing PrEP offer, evaluation, and uptake. The minimal estimated 
cost of the project, and significant cost avoidance and ROI, via health insurance reimbursement 
estimates, demonstrate the HIV risk screening protocol’s cost-efficiency. Similar to other brief 
screening tools used in primary care, the HIV PrEP screening tool for identifying HIV risk and 
PrEP offer represents a useful clinical tool in the primary care setting, especially those in 
endemic areas, for optimizing PrEP implementation and improving HIV prevention.  
Implications for practice and future research were derived from the implementation of 
this DNP project. Because STI infection represents one of the HIV risk criteria per CDC 
guidelines, as patients with a history of STI infection have a higher susceptibility for acquiring 
HIV, it is important to note the severity of the potential consequences of not capturing these 
patients for PrEP offer (CDC, 2014) (Hoover et al., 2016). To effectively optimize PrEP 
implementation in the primary care setting, as well as further improve clinical practice at API, 
the relationship between STI testing/treatment and HIV risk screening for PrEP offer must be 
emphasized and reinforced to clinical staff. Implications for future research include the 
opportunity to evaluate the effectiveness of the HIV risk screening protocol if implemented at 
other San Francisco primary care clinics; validate the HIV PrEP screening tool; and assess the 
HIV PREP   37 
 
HIV risk screening protocol’s impact on San Francisco’s HIV transmission rate and contribution 
to Getting to Zero San Francisco. 
Other Information 
Funding 
 No internal or external funding was provided for any part in this DNP project, as its costs 
were absorbed into API’s FTE budget. Therefore, funding played no major role in its design, 
implementation, and interpretation. 
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Appendix A 
Definition of Terms 
API: Asian and Pacific Islander Wellness Center 
AUDIT-C: Alcohol Use Disorders Identification Test - Consumption 
CDC: Centers for Disease Control and Prevention 
CMO: Chief Medical Officer 
DNP: Doctorate of Nursing Practice 
EHR: Electronic Health Record 
FQHC: Federally Qualified Health Center 
FTE: Full Time Equivalent 
HIRI-MSM: HIV Incidence Risk Index for Men who have Sex with Men 
HIPAA: Health Insurance Portability and Accountability Act 
HIV: Human Immunodeficiency Virus 
IDU: Intravenous Drug User 
IRB: Institutional Review Board 
JHNEBP: Johns Hopkins Nursing Evidence Based Practice 
LGBTQ: Lesbian, Gay, Bisexual, Transgender, Queer 
MA: Medical Assistant 
MSM: Men who have Sex with Men 
NP: Nurse Practitioner  
PHQ: Patient Health Questionnaire 
PrEP: Pre-exposure Prophylaxis against HIV Infection 
RCT: Randomized Controlled Trials 
ROI: Return on Investment 
STI: Sexually Transmitted Infection 
TDF/FTC: Tenofovir Disoproxil Fumarate/Emtricitabine 
UNAIDS: United Nations Program on HIV/AIDS 
USF: University of San Francisco 
US: United States 
WHO: World Health Organization 
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Appendix B 
CDC Guidelines for Detecting Substantial Risk for Acquiring HIV 
Men who have sex with men Heterosexual men and 
women 
Injection drug users 
HIV-positive sexual partner 
 
Recent bacterial STI 
 
High number of sex partners 
 
History of inconsistent or no 
condom use 
 
Commercial sex work 
HIV-positive sexual partner 
 
Recent bacterial STI 
 
High number of sex partners 
 
History of inconsistent or no 
condom use 
 
Commercial sex work 
 
In high-prevalence area or 
network 
 
HIV-positive injecting 
partner 
 
Sharing injection equipment 
 
Recent drug treatment (but 
currently injection) 
 
*Note: Adapted from the Centers for Disease Control and Prevention. (2014). Preexposure prophylaxis for the prevention of HIV 
infection in the United States: A clinical practice guideline. Retrieved from: https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf  
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Appendix C 
Baseline Clinical Data Assessment 
 
 
* Note: Based on data from chart reviews of medical encounters for ordered STI testing from December 7, 2015 to April 8, 2016 
(n =88). 
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Appendix D 
PrEP Efficacy Evidence Tables using JHNEBP Research Evidence Appraisal 
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PrEP Efficacy Evidence Tables using JHNEBP Research Evidence Appraisal (continued) 
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 r
is
k
 o
f 
H
IV
 i
n
fe
ct
io
n
, 
re
g
ar
d
le
ss
 o
f 
ag
e,
 
g
en
d
er
, 
re
g
im
en
 
(T
D
F
 V
S
 
T
D
F
/F
T
C
),
 &
 m
o
d
e 
o
f 
in
fe
ct
io
n
. 
 
S
ig
n
if
ic
an
t 
H
IV
 
re
d
u
ct
io
n
 i
n
 h
ig
h
 
an
d
 m
o
d
er
at
e 
ad
h
er
en
ce
 g
ro
u
p
; 
n
o
 
ef
fe
ct
 i
n
 l
o
w
 
ad
h
er
en
ce
 g
ro
u
p
. 
M
ea
su
re
m
en
t 
H
IV
 i
n
fe
ct
io
n
 i
n
 
T
D
F
 v
s 
T
D
F
/F
T
C
 v
s 
p
la
ce
b
o
. 
P
rE
P
 
ef
fe
ct
iv
en
es
s 
in
 
h
ig
h
 a
d
h
er
en
ce
 
g
ro
u
p
 (
>
7
0
%
 
se
ru
m
 d
ru
g
 
d
et
ec
ti
o
n
) 
v
s 
m
o
d
er
at
e 
ad
h
er
en
ce
 (
4
1
-
7
0
%
 d
ru
g
 
d
et
ec
ti
o
n
) 
v
s 
lo
w
 a
d
h
er
en
ce
 
g
ro
u
p
 (
<
4
0
%
 
d
ru
g
 d
et
ec
ti
o
n
).
  
D
ru
g
 r
es
is
ta
n
ce
 
to
 F
T
C
 i
n
 H
IV
 
+
 s
u
b
je
ct
s 
(=
 
lo
w
).
 
M
a
jo
r 
V
a
ri
a
b
le
s 
H
IV
 i
n
fe
ct
io
n
 
 G
u
id
el
in
e 
re
co
m
m
en
d
at
io
n
 b
as
ed
 o
n
 t
h
e 
fo
ll
o
w
in
g
 
cr
it
er
ia
: 
 R
at
io
n
al
e 
&
 
su
p
p
o
rt
in
g
 
ev
id
en
ce
 
B
en
ef
it
s 
v
s 
h
ar
m
 
C
o
st
 &
 c
o
st
-
ef
fe
ct
iv
en
es
s 
E
q
u
it
y
 &
 
ac
ce
p
ta
b
il
it
y
 
F
ea
si
b
il
it
y
 
Im
p
le
m
en
ta
ti
o
n
 
co
n
si
d
er
at
io
n
s 
R
es
ea
rc
h
 g
ap
s.
 
S
a
m
p
le
/ 
S
et
ti
n
g
 
1
4
 R
C
T
s,
 
3
 
o
b
se
rv
at
io
n
al
 
st
u
d
ie
s,
 
st
u
d
ie
s 
in
 
ac
co
rd
an
ce
 
w
/ 
P
R
IS
M
A
 
re
p
o
rt
in
g
 
g
u
id
el
in
es
 
 S
et
ti
n
g
s:
 
T
ri
al
s 
co
n
d
u
ct
ed
 i
n
 
In
d
ia
, 
In
d
o
n
es
ia
, 
K
en
y
a,
 P
er
u
, 
P
o
rt
u
g
al
, 
U
k
ra
in
e,
 
Z
am
b
ia
 a
n
d
 
Z
im
b
ab
w
e.
 
  
D
es
ig
n
/ 
M
et
h
o
d
 
G
u
id
el
in
e 
b
as
ed
 o
n
: 
 S
y
st
em
at
i
c 
R
ev
ie
w
 
&
 m
et
a-
an
al
y
si
s 
 Q
u
al
it
at
i
v
e 
L
it
er
at
u
re
 
R
ev
ie
w
s 
 E
x
te
rn
al
 
p
ee
r 
re
v
ie
w
  
C
o
n
ce
p
tu
a
l 
F
ra
m
ew
o
rk
 
C
o
m
p
re
h
en
si
v
e 
re
v
is
io
n
 
o
f 
2
0
1
3
 
g
u
id
el
in
es
 
b
as
ed
 o
n
 
n
ew
 
ev
id
en
ce
 &
 
le
ss
o
n
s 
fr
o
m
 
im
p
le
m
en
ta
ti
o
n
 t
h
ro
u
g
h
 
Ju
n
e 
2
0
1
5
 
v
ia
 C
li
n
ic
al
 
G
u
id
el
in
e 
D
ev
el
o
p
m
en
t 
G
ro
u
p
. 
C
it
a
ti
o
n
 
W
H
O
 (
2
0
1
5
).
 
G
u
id
el
in
e 
o
n
 
W
h
en
 t
o
 S
ta
rt
 
A
n
ti
re
tr
o
vi
ra
l 
T
h
er
a
p
y 
a
n
d
 
o
n
 P
re
-
E
xp
o
su
re
 
P
ro
p
h
yl
a
xi
s 
fo
r 
H
IV
. 
W
o
rl
d
 H
ea
lt
h
 
O
rg
an
iz
at
io
n
: 
S
w
it
ze
rl
an
d
. 
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Appendix E 
 
PrEP Implementation Evidence Tables using JHNEBP Research Evidence Appraisal 
 
A
p
p
r
a
is
a
l 
N
o
n
-
ex
p
er
im
en
t-
al
 s
tu
d
y
 
 L
im
it
at
io
n
s
: 
lo
w
 H
IV
 
ri
sk
 
p
er
ce
p
ti
o
n
, 
la
ck
 o
f 
p
ro
v
id
er
 
k
n
o
w
le
d
g
e 
ab
o
u
t 
P
rE
P
. 
N
o
 c
o
n
tr
o
l 
g
ro
u
p
. 
 S
tr
en
g
th
 o
f 
E
v
id
en
ce
: 
 
L
ev
el
 3
 
Q
u
al
it
y
 C
 
Q
u
al
it
at
iv
e 
st
u
d
y
 
 L
im
it
at
io
n
s
: 
n
o
 c
o
n
tr
o
l 
g
ro
u
p
  
 S
tr
en
g
th
 o
f 
E
v
id
en
ce
: 
 
L
ev
el
 3
 
Q
u
al
it
y
 B
 
F
in
d
in
g
s 
 
E
d
u
ca
te
d
 a
b
o
u
t 
P
rE
P
: 
2
3
4
 
In
te
re
st
ed
 i
n
 P
rE
P
: 
5
6
%
 
R
ec
ei
v
ed
 f
o
ll
o
w
-u
p
 s
co
n
ta
ct
: 
5
3
%
 o
f 
th
o
se
 i
n
te
re
st
ed
 
S
ch
ed
u
le
d
 p
ro
v
id
er
 
ap
p
o
in
tm
en
t:
 5
1
%
 o
f 
th
o
se
 
w
h
o
 f
o
ll
o
w
ed
 u
p
 
A
tt
en
d
ed
 p
ro
v
id
er
 
ap
p
o
in
tm
en
t:
 7
7
%
 o
f 
th
o
se
 
w
h
o
 s
ch
d
u
le
d
 a
n
 a
p
p
o
in
tm
en
t 
In
it
ia
te
d
 P
rE
P
 (
rc
ei
v
ed
 R
x
):
 
9
5
%
 o
f 
th
o
se
 w
h
o
 a
tt
en
d
ed
 t
h
e 
ap
p
o
in
tm
en
t 
R
ea
so
n
s 
fo
r 
la
ck
 o
f 
in
te
re
st
 i
n
 
P
rE
P
: 
3
7
%
 l
o
w
 H
IV
 r
is
k
 
p
er
ce
p
ti
o
n
; 
1
0
%
 m
o
re
 t
im
e 
to
 
co
n
si
d
er
; 
7
%
 c
o
n
ce
rn
 a
b
o
u
t 
si
d
e 
ef
fe
ct
s;
 3
%
 f
in
an
ci
al
 
b
ar
ri
er
s 
R
ea
so
n
 f
o
r 
n
o
t 
sc
h
ed
u
li
n
g
 a
n
 
ap
p
o
in
tm
en
t:
 l
o
w
 H
IV
 r
is
k
 
p
er
ce
p
ti
o
n
. 
P
ar
ti
ci
p
an
ts
 w
h
o
 w
er
e 
se
lf
-
re
fe
rr
ed
, 
th
o
se
 w
it
h
 p
re
v
io
u
s 
P
rE
P
 a
w
ar
en
es
s,
 a
n
d
 t
h
o
se
 
re
p
o
rt
in
g
 >
 1
 e
p
is
o
d
e 
o
f 
an
al
 
se
x
 w
it
h
 a
n
 H
IV
-p
o
si
ti
v
e 
p
ar
tn
er
 i
n
 t
h
e 
la
st
 1
2
 m
o
n
th
s 
w
er
e 
m
o
re
 l
ik
el
y
 t
o
 e
n
ro
ll
. 
 
9
8
%
 o
f 
en
ro
ll
ed
 p
ar
ti
ci
p
an
ts
 
w
er
e 
M
S
M
. 
A
t 
b
as
el
in
e,
 
6
3
.5
%
 o
f 
M
S
M
 r
ep
o
rt
ed
 
co
n
d
o
m
le
ss
 r
ec
ep
ti
v
e 
an
al
 s
ex
 
in
 t
h
e 
p
re
v
io
u
s 
3
 m
o
n
th
s.
 
O
v
er
al
l,
 i
n
te
re
st
 i
n
 P
rE
P
 i
s 
h
ig
h
 a
m
o
n
g
 a
 d
iv
er
se
 
p
o
p
u
la
ti
o
n
 o
f 
at
-r
is
k
 M
S
M
 
w
h
en
 o
ff
er
ed
 a
t 
S
T
D
 o
r 
co
m
m
u
n
it
y
 h
ea
lt
h
 c
li
n
ic
s.
 
D
a
ta
 
A
n
a
ly
si
s 
B
iv
ar
ia
te
 
an
d
 m
u
lt
i-
v
ar
ia
b
le
 
lo
g
is
ti
c 
re
g
re
ss
-
io
n
 m
o
d
el
s 
to
 e
x
am
in
e 
p
re
d
ic
t-
o
rs
 
o
f 
P
rE
P
 
in
it
ia
ti
o
n
. 
 M
u
lt
i-
v
ar
ia
b
le
 
P
o
is
so
n
 
re
g
re
ss
-
io
n
 m
o
d
el
 
as
se
ss
ed
 
p
re
d
ic
t-
o
rs
 
o
f 
en
ro
ll
-
m
en
t.
  
M
u
lt
i-
v
ar
ia
b
le
 
d
es
cr
ip
t-
iv
e 
st
at
is
ti
ca
l 
an
al
y
se
s 
o
f 
p
ar
ti
ci
-
p
an
t 
ch
ar
ac
te
r-
is
ti
cs
. 
 
M
ea
su
re
m
en
t 
N
u
m
b
er
 o
f 
p
ar
ti
ci
p
an
ts
 
in
cl
u
d
ed
 i
n
 t
h
e 
fo
ll
o
w
in
g
 s
te
p
s 
o
f 
th
e 
P
rE
P
 
im
p
le
m
en
ta
-
ti
o
n
 c
as
ca
d
e:
  
E
d
u
ca
te
d
 a
b
o
u
t 
P
rE
P
; 
in
te
re
st
ed
 i
n
 
P
rE
P
; 
re
ce
iv
ed
 
fo
ll
o
w
-u
p
 
co
n
ta
ct
; 
sc
h
ed
u
le
d
 
p
ro
v
id
er
 
ap
p
o
in
tm
en
t;
 
at
te
n
d
ed
 
p
ro
v
id
er
 
ap
p
o
in
tm
en
t;
 
in
it
ia
te
d
 P
rE
P
 
(r
ec
ei
v
ed
 R
x
).
 
 P
ar
ti
ci
p
an
t 
en
ro
ll
m
en
t,
 
H
IV
 r
is
k
 
b
eh
av
io
rs
, 
P
rE
P
 
aw
ar
en
es
s,
 
in
te
re
st
 i
n
 
P
rE
P
. 
M
a
jo
r
 
V
a
r
ia
b
le
s 
L
ac
k
 o
f 
in
te
re
st
. 
L
ac
k
 o
f 
p
at
ie
n
t 
ac
ce
p
ta
b
il
it
y
 o
f 
P
rE
P
. 
P
rE
P
 
el
ig
ib
il
it
y
 
cr
it
er
ia
. 
S
cr
ee
n
in
g
 
p
ar
ti
ci
p
an
ts
 
fo
r 
P
rE
P
. 
E
n
ro
ll
m
en
t 
o
f 
p
ar
ti
ci
p
an
ts
 
in
 s
tu
d
y
. 
P
rE
P
 u
p
ta
k
e.
 
S
o
ci
o
-
d
em
o
g
ra
p
h
-
ic
s,
 &
 s
ex
u
al
 
&
 d
ru
g
 u
se
 
b
eh
av
io
rs
. 
H
IV
 r
is
k
 
p
er
ce
p
ti
o
n
. 
P
re
p
 
aw
ar
en
es
s.
 
S
a
m
p
le
/ 
S
e
tt
in
g
 
N
ew
 
E
n
g
la
n
d
 
S
ex
u
al
ly
 
T
ra
n
s-
m
it
te
d
 
D
is
ea
se
s 
C
li
n
ic
 
N
=
2
3
4
 
M
S
M
. 
 N
=
 5
5
7
 
S
T
D
 
cl
in
ic
s 
in
 
S
an
 
F
ra
n
ci
s-
co
 &
 
M
ia
m
i:
 
M
S
M
 &
 
tr
an
s-
g
en
d
er
 
w
o
m
en
. 
C
o
m
m
-
u
n
it
y
 
h
ea
lt
h
 
ce
n
te
r 
in
 
W
as
h
in
g
-t
o
n
, 
D
C
: 
M
S
M
 &
 
tr
an
s-
g
en
d
er
 
w
o
m
en
. 
 
D
e
si
g
n
/ 
M
e
th
o
d
 
D
em
o
n
st
ra
ti
o
n
 p
ro
je
ct
  
M
et
h
o
d
: 
E
v
er
y
 M
S
M
 s
ee
k
in
g
 
S
T
D
 r
el
at
ed
 s
er
v
ic
es
 w
er
e 
o
ff
er
ed
 e
d
u
ca
ti
o
n
 o
n
 P
rE
P
. 
If
 
ag
re
ea
b
le
, 
th
ey
 w
er
e 
p
ro
v
id
ed
 
P
rE
P
 e
d
u
ca
ti
o
n
. 
T
h
ei
r 
in
te
re
st
 
in
 P
rE
P
 w
as
 t
h
en
 a
ss
es
se
d
. 
F
o
r 
th
o
se
 i
n
te
re
st
ed
 i
n
 P
rE
P
, 
fo
ll
o
w
-u
p
 w
as
 c
o
n
d
u
ct
ed
 t
o
 
sc
h
ed
u
le
 a
n
 a
p
p
o
in
tm
en
t 
w
it
h
 
a 
p
ro
v
id
er
 f
o
r 
ev
al
u
at
io
n
 t
o
 
in
it
ia
te
 P
rE
P
. 
F
o
r 
th
o
se
 w
h
o
 
k
ep
t 
th
ei
r 
p
ro
v
id
er
 
ap
p
o
in
tm
en
ts
 a
n
d
 m
et
 P
rE
P
 
cr
it
er
ia
, 
th
ey
 w
er
e 
p
re
sc
ri
b
ed
 
P
rE
P
. 
B
ri
ef
 q
u
e
st
io
n
n
ai
re
 
as
se
ss
ed
 r
ea
so
n
s 
b
eh
in
d
 
p
at
ie
n
ts
’ 
la
ck
 o
f 
in
te
re
st
 o
r 
re
fu
sa
l 
to
 i
n
it
ia
te
 P
rE
P
. 
  
P
ro
sp
ec
ti
v
e,
 l
o
n
g
it
u
d
in
al
 o
p
en
-
la
b
el
 c
o
h
o
rt
 s
tu
d
y
. 
M
et
h
o
d
: 
M
S
M
 a
n
d
 t
ra
n
sg
en
d
er
 
w
o
m
en
 w
er
e 
ta
rg
et
ed
 a
n
d
 
p
re
sc
re
en
ed
 f
o
r 
re
fe
rr
al
 t
o
 
p
ar
ti
ci
p
at
e 
in
 t
h
e 
st
u
d
y
, 
th
en
 
sc
re
en
ed
 f
o
r 
P
rE
P
 e
li
g
ib
il
it
y
, 
fo
ll
o
w
ed
 b
y
 c
o
m
p
le
ti
o
n
 o
f 
a 
d
et
ai
le
d
 i
n
te
rv
ie
w
er
-
ad
m
in
is
te
re
d
 q
u
es
ti
o
n
n
ai
re
 o
n
 
d
em
o
g
ra
p
h
ic
s 
an
d
 s
ex
u
al
 a
n
d
 
d
ru
g
-u
se
 b
eh
av
io
rs
. 
 T
h
o
se
 
w
h
o
 c
le
ar
ed
 P
rE
P
 s
cr
ee
n
in
g
 
w
er
e 
“e
n
ro
ll
ed
” 
fo
r 
P
rE
P
 
in
it
ia
ti
o
n
 a
n
d
 r
ec
ei
v
ed
 
T
D
F
/F
T
C
 a
t 
n
o
 c
o
st
 f
o
r 
4
8
 
w
ee
k
s.
 
C
o
n
c
e
p
tu
a
l 
F
r
a
m
e
w
o
r
k
 
A
n
al
y
si
s 
o
f 
g
ap
s 
in
 P
rE
P
 
im
p
le
-
m
en
ta
-
ti
o
n
 
ca
sc
ad
e.
 
A
ss
es
s-
m
en
t 
o
f 
P
rE
P
 
d
el
iv
er
y
 
in
 
m
u
n
ic
i-
p
al
  
h
ea
lt
h
 
ca
re
 
se
tt
in
g
s.
 
C
it
a
ti
o
n
 
C
h
an
, 
P
. 
A
.,
 G
ly
n
n
, 
T
. 
R
.,
 O
ld
en
b
u
rg
, 
C
. 
E
.,
 
M
o
n
tg
o
m
er
y
, 
M
. 
C
.,
 
R
o
b
in
et
te
, 
A
. 
E
.,
 
A
lm
o
n
te
, 
A
.,
 
…
 N
u
n
n
, 
A
. 
S
. 
(2
0
1
6
).
 
Im
p
le
m
en
ta
ti
o
n
 o
f 
p
re
ex
p
o
su
re
 p
ro
p
h
y
la
x
is
 
fo
r 
h
u
m
an
 
im
m
u
n
o
d
ef
ic
ie
n
cy
 v
ir
u
s 
p
re
v
en
ti
o
n
 a
m
o
n
g
 m
en
 
w
h
o
 h
av
e 
se
x
 w
it
h
 m
en
 
at
 a
 N
ew
 
E
n
g
la
n
d
 s
ex
u
al
ly
 
tr
an
sm
it
te
d
 d
is
ea
se
s 
cl
in
ic
. 
S
ex
u
a
ll
y 
T
ra
n
sm
it
te
d
 D
is
ea
se
s,
 
4
3
(1
1
),
  
4
1
7
-4
2
2
. 
 
 C
o
h
en
, 
S
. 
E
.,
 
V
it
ti
n
g
h
o
ff
, 
E
.,
 B
ac
o
n
, 
O
.,
 D
o
b
le
ck
i-
L
ew
is
, 
S
.,
 
P
o
st
le
, 
B
. 
S
.,
 F
ea
st
er
, 
D
. 
J.
,…
L
iu
, 
A
. 
Y
. 
(2
0
1
5
).
 
H
ig
h
 i
n
te
re
st
 i
n
 
p
re
ex
p
o
su
re
 p
ro
p
h
y
la
x
is
 
am
o
n
g
 m
en
 w
h
o
 h
av
e 
se
x
 w
it
h
 m
en
 a
t 
ri
sk
 f
o
r 
H
IV
 i
n
fe
ct
io
n
: 
b
as
el
in
e 
d
at
a 
fr
o
m
 t
h
e 
U
S
 P
rE
P
 
d
em
o
n
st
ra
ti
o
n
 p
ro
je
ct
. 
A
cq
u
ir
ed
 I
m
m
u
n
e 
D
ef
ic
ie
n
cy
 S
yn
d
ro
m
e,
 
6
8
(4
),
 4
3
9
-4
4
8
. 
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PrEP Implementation Evidence Tables using JHNEBP Research Evidence Appraisal (continued) 
 
A
p
p
r
a
is
a
l 
Q
u
al
it
at
iv
e 
st
u
d
y
. 
L
im
it
at
io
n
s:
 
p
o
te
n
ti
al
 
b
ia
s 
fr
o
m
 
ar
b
it
ra
ry
 
th
em
e 
d
ev
el
o
p
m
en
t 
b
y
 s
tu
d
y
 
te
am
 
m
em
b
er
s 
co
m
p
ro
m
is
e
s 
v
al
id
it
y
. 
S
tr
en
g
th
 o
f 
ev
id
en
ce
: 
 
L
ev
el
 3
 
Q
u
al
it
y
 C
 
M
et
a-
sy
n
th
es
is
. 
L
im
it
at
io
n
s:
 
M
et
h
o
d
s 
n
o
t 
d
is
cu
ss
ed
. 
U
n
k
n
o
w
n
 
sa
m
p
le
 s
iz
e.
 
L
o
w
 i
n
te
rn
al
 
v
al
id
it
y
. 
S
tr
en
g
th
 o
f 
E
v
id
en
ce
: 
 
L
ev
el
 3
 
Q
u
al
it
y
 C
 
F
in
d
in
g
s 
 
T
h
em
es
 s
u
rr
o
u
n
d
in
g
 
P
rE
P
: 
n
ee
d
 f
o
r 
 
in
cr
ea
se
d
 p
ro
v
id
er
 
k
n
o
w
le
d
g
e 
ab
o
u
t 
P
rE
P
; 
p
er
ce
p
ti
o
n
 o
f 
lo
w
 P
rE
P
 d
em
an
d
 
am
o
n
g
 p
at
ie
n
ts
; 
co
st
 
an
d
 r
is
k
 a
ss
es
sm
en
t 
as
 p
er
ce
iv
ed
 b
ar
ri
er
s 
to
 P
rE
P
; 
co
n
ce
rn
s 
ab
o
u
t 
ad
h
er
en
ce
 a
n
d
 
ri
sk
 c
o
m
p
en
sa
ti
o
n
. 
 B
ar
ri
er
s 
to
 P
rE
P
: 
 
P
rE
P
 e
ff
ic
ac
y
 &
 
m
ed
ic
at
io
n
 a
d
h
er
en
ce
; 
p
ro
v
id
er
 l
o
g
is
ti
cs
; 
p
o
te
n
ti
al
 u
n
in
te
n
d
ed
 
cl
in
ic
al
 c
o
n
se
q
u
en
ce
s 
(A
R
V
 d
ru
g
 r
es
is
ta
n
ce
 
P
rE
P
 d
ru
g
 t
o
x
ic
it
y
);
 
b
eh
av
io
ra
l 
d
is
in
h
ib
it
io
n
 &
 S
T
Is
. 
P
u
rv
ie
w
 P
ar
ad
o
x
: 
H
IV
 
sp
ec
ia
li
st
s 
h
av
e 
h
ig
h
er
 
P
rE
P
 a
w
ar
en
es
s 
th
an
 
P
C
P
s.
 P
ra
ct
ic
e 
re
co
m
m
en
d
at
io
n
s:
  
In
cr
ea
se
 p
ro
v
id
er
 
ed
u
ca
ti
o
n
 &
 t
ra
in
in
g
 
o
n
 P
rE
P
. 
O
p
ti
m
iz
e 
m
ed
ic
at
io
n
 a
d
h
er
en
ce
 
an
d
 P
rE
P
 a
cc
ep
ta
b
il
it
y
 
th
ro
u
g
h
 c
o
m
m
u
n
it
y
 
en
g
ag
em
en
t.
 I
m
p
ro
v
e 
id
en
ti
fi
ca
ti
o
n
 o
f 
ap
p
ro
p
ri
at
e 
p
at
ie
n
ts
 
fo
r 
P
rE
P
. 
 
D
a
ta
 A
n
a
ly
si
s 
A
u
d
io
 r
ec
o
rd
in
g
s 
o
f 
fo
cu
s 
g
ro
u
p
 
d
is
cu
ss
io
n
s 
w
er
e 
tr
an
sc
ri
b
ed
. 
 
T
ra
n
sc
ri
p
ts
 
u
p
lo
ad
ed
 t
o
 
D
ed
o
o
se
 v
er
si
o
n
 
5
.0
.1
1
 f
o
r 
an
al
y
si
s.
 
O
p
en
 c
o
d
in
g
 o
f 
tr
an
sc
ri
p
ts
 f
u
rt
h
er
 
d
ev
el
o
p
ed
 t
h
em
es
. 
C
o
d
ed
 t
ra
n
sc
ri
p
ts
 
w
er
e 
re
v
ie
w
ed
 b
y
 
st
u
d
y
 t
ea
m
 
m
em
b
er
s,
 r
es
o
lv
in
g
 
d
if
fe
re
n
ce
s 
b
y
 
d
is
cu
ss
io
n
 a
n
d
 
m
u
tu
al
 a
g
re
em
en
t,
 
fo
r 
ac
cu
ra
cy
. 
 S
u
m
m
ar
iz
es
 
fi
n
d
in
g
s 
fr
o
m
 
p
re
v
io
u
s 
st
u
d
ie
s,
 
o
th
er
w
is
e 
n
o
t 
sp
ec
if
ie
d
. 
M
e
a
su
r
e
m
e
n
t 
T
h
em
es
 d
er
iv
ed
 
fr
o
m
 f
o
cu
s 
g
ro
u
p
 
d
is
cu
ss
io
n
s.
 
B
ar
ri
er
s 
to
 P
rE
P
 
“r
ea
l 
w
o
rl
d
” 
ef
fe
ct
iv
en
es
s.
 
P
o
te
n
ti
al
 
u
n
in
te
n
d
ed
 
cl
in
ic
al
 
co
n
se
q
u
en
ce
s.
 
P
u
rv
ie
w
 P
ar
ad
o
x
. 
M
a
jo
r
 
V
a
r
ia
b
le
s 
S
ta
ff
 p
er
ce
p
ti
o
n
s 
o
f:
 P
rE
P
 
im
p
le
m
en
ta
ti
o
n
 
p
ra
ct
ic
e;
 P
rE
P
 
in
te
re
st
 a
m
o
n
g
 
p
at
ie
n
ts
; 
P
rE
P
 
ac
ce
p
ta
b
il
it
y
 
am
o
n
g
 p
at
ie
n
ts
 
an
d
 p
ro
v
id
er
s;
 
co
n
ce
rn
s 
an
d
 
b
ar
ri
er
s 
to
 P
rE
P
. 
 P
ro
v
id
er
 
b
eh
av
io
r,
 
at
ti
tu
d
es
, 
an
d
 
in
te
n
ti
o
n
s 
to
w
ar
d
 P
rE
P
 
p
ro
v
is
io
n
. 
S
a
m
p
le
/ 
S
e
tt
in
g
 
N
=
 2
2
 c
li
n
ic
 
st
af
f 
4
 c
o
m
m
u
n
it
y
 
h
ea
lt
h
 c
en
te
rs
 
in
 
so
u
th
ea
st
er
n
 
F
lo
ri
d
a,
 3
 o
f 
w
h
ic
h
 a
re
 
F
Q
H
C
s.
  
 M
u
lt
ip
le
 
st
u
d
ie
s.
 E
x
ac
t 
n
u
m
b
er
 n
o
r 
sp
ec
if
ie
d
. 
 
D
e
si
g
n
/ 
M
e
th
o
d
 
Q
u
al
it
at
iv
e 
st
u
d
y
 o
f 
fo
cu
s 
g
ro
u
p
 
d
is
cu
ss
io
n
 t
h
em
es
 
 M
et
h
o
d
: 
6
-7
 s
ta
ff
 
m
em
b
er
s 
fr
o
m
 e
ac
h
 
cl
in
ic
 w
er
e 
in
te
rv
ie
w
ed
. 
B
ri
ef
 
d
em
o
g
ra
p
h
ic
 
b
ac
k
g
ro
u
n
d
 
in
fo
rm
at
io
n
 w
as
 
co
ll
ec
te
d
, 
an
d
 f
o
cu
s 
g
ro
u
p
 d
is
cu
ss
io
n
s 
w
er
e 
m
o
d
er
at
ed
 b
y
 
a 
st
u
d
y
 i
n
v
es
ti
g
at
o
r 
u
si
n
g
 a
 s
em
i-
st
ru
ct
u
re
d
 g
u
id
e.
 
N
ar
ra
ti
v
e 
re
v
ie
w
 
 M
et
h
o
d
: 
P
re
v
io
u
s 
q
u
al
it
at
iv
e 
st
u
d
ie
s 
o
f 
p
ro
v
id
er
 
b
eh
av
io
r,
 a
tt
it
u
d
es
, 
an
d
 i
n
te
n
ti
o
n
s 
to
w
ar
d
 P
rE
P
 
p
ro
v
is
io
n
 w
er
e 
su
m
m
ar
iz
ed
 t
o
 
d
ev
el
o
p
 p
ra
ct
ic
e 
re
co
m
m
en
d
at
io
n
s 
to
 o
p
ti
m
iz
e 
P
rE
P
 i
n
 
th
e 
p
ri
m
ar
y
 c
ar
e 
se
tt
in
g
. 
C
o
n
c
e
p
tu
a
l 
F
r
a
m
e
w
o
r
k
 
F
o
cu
s 
g
ro
u
p
 
st
u
d
y
 t
o
 e
x
p
lo
re
 
th
e 
fe
as
ib
il
it
y
, 
ac
ce
p
ta
b
il
it
y
, 
an
d
 u
p
ta
k
e 
o
f 
P
rE
P
 i
n
 a
n
 
en
d
em
ic
 a
re
a.
 
P
ra
ct
ic
e 
re
co
m
m
en
d
-
at
io
n
s 
C
it
a
ti
o
n
 
D
o
b
le
ck
i-
L
ew
is
, 
S
.,
 &
 J
o
n
es
, 
D
. 
(2
0
1
6
).
 
C
o
m
m
u
n
it
y
 
fe
d
er
al
ly
 
q
u
al
if
ie
d
 h
ea
lt
h
 
ce
n
te
rs
 a
s 
h
o
m
es
 
fo
r 
H
IV
 
p
re
ex
p
o
su
re
 
p
ro
p
h
y
la
x
is
: 
p
er
sp
ec
ti
v
es
 
fr
o
m
 s
o
u
th
 
F
lo
ri
d
a.
 J
o
u
rn
a
l 
o
f 
th
e 
In
te
rn
a
ti
o
n
a
l 
A
ss
o
ci
a
ti
o
n
 o
f 
P
ro
vi
d
er
s 
o
f 
A
ID
S
 C
a
re
, 
1
5
(6
),
 5
2
2
-5
2
8
. 
 
 
S
il
ap
as
w
an
, 
A
.,
 
K
ra
k
o
w
er
, 
K
.,
 &
 
M
ay
er
, 
K
. 
H
. 
(2
0
1
6
).
 P
re
-
ex
p
o
su
re
 
p
ro
p
h
y
la
x
is
: 
a 
n
ar
ra
ti
v
e 
re
v
ie
w
 
o
f 
p
ro
v
id
er
 
b
eh
av
io
r 
an
d
 
in
te
rv
en
ti
o
n
s 
to
 
in
cr
ea
se
 P
rE
P
 
im
p
le
m
en
ta
ti
o
n
 
in
 p
ri
m
ar
y
 c
ar
e.
 
Jo
u
rn
a
l 
o
f 
G
en
er
a
l 
In
te
rn
a
l 
M
ed
ic
in
e,
 3
2
(2
),
 
1
9
2
-1
9
8
. 
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A
p
p
r
a
is
a
l 
M
et
a-
sy
n
th
es
is
. 
L
im
it
at
io
n
s:
 n
o
 t
ri
al
s 
st
u
d
ie
d
. 
M
et
h
o
d
 n
o
t 
d
is
cu
ss
ed
. 
N
o
 
ev
al
u
at
io
n
 o
f 
ef
fe
ct
iv
en
es
s 
o
f 
m
o
d
el
s 
fo
r 
p
ra
ct
ic
e.
 
S
tr
en
g
th
 o
f 
E
v
id
en
ce
: 
L
ev
el
 3
 
Q
u
al
it
y
 C
 
Q
u
al
it
at
iv
e 
st
u
d
y
. 
 
L
im
it
at
io
n
s:
 
p
o
te
n
ti
al
 b
ia
s 
si
n
ce
 
in
te
rv
ie
w
 c
o
n
te
n
t 
w
as
 c
o
d
ed
 b
y
 s
tu
d
y
 
te
am
 m
em
b
er
s,
 
w
h
ic
h
 c
o
m
p
ro
m
is
es
 
in
te
rn
al
 v
al
id
it
y
. 
S
tr
en
g
th
 o
f 
E
v
id
en
ce
: 
L
ev
el
 3
 
Q
u
al
it
y
 C
 
F
in
d
in
g
s 
 
H
ig
h
-r
is
k
 p
at
ie
n
t 
p
o
p
u
la
ti
o
n
s 
d
is
p
ro
p
o
rt
io
n
at
el
y
 s
ee
k
 c
ar
e 
at
 S
T
D
 
cl
in
ic
s,
 a
n
d
 S
T
D
 i
n
fe
ct
io
n
s 
in
cr
ea
se
 
th
e 
su
sc
ep
ti
b
il
it
y
 f
o
r 
H
IV
 
ac
q
u
is
it
io
n
, 
th
er
ef
o
re
 S
T
D
 c
li
n
ic
s 
ar
e 
th
e 
o
p
ti
m
al
 s
et
ti
n
g
 f
o
r 
P
rE
P
 
im
p
le
m
en
ta
ti
o
n
. 
 
R
ec
o
m
m
en
d
at
io
n
s:
 
M
o
d
el
 1
: 
P
rE
P
 s
er
v
ic
es
 p
ro
v
id
ed
 
d
ir
ec
tl
y
 a
t 
S
T
D
 c
li
n
ic
. 
M
o
d
el
 2
: 
S
T
D
 c
li
n
ic
 c
ap
tu
re
s 
P
rE
P
 
el
ig
ib
le
 p
at
ie
n
t 
an
d
 p
ro
v
id
es
 r
ef
er
ra
l 
to
 a
 P
rE
P
 p
ro
v
id
er
 i
n
 t
h
e 
co
m
m
u
n
it
y
. 
 
A
 d
iv
er
se
 g
ro
u
p
 o
f 
p
ar
ti
ci
p
an
ts
 
fa
v
o
re
d
 P
rE
P
 i
m
p
le
m
en
ta
ti
o
n
 i
n
 
n
o
n
-H
IV
 s
p
ec
ia
lt
y
 s
et
ti
n
g
s,
 b
u
t 
w
er
e 
d
iv
id
ed
 o
n
 w
h
et
h
er
 t
h
ey
 t
h
o
u
g
h
t 
p
ri
m
ar
y
 c
ar
e 
p
ro
v
id
er
s 
co
u
ld
 a
ch
ie
v
e 
al
l 
th
e 
sk
il
ls
 a
n
d
 s
er
v
ic
es
 e
sp
o
u
se
d
 
w
it
h
 P
rE
P
 p
ro
v
is
io
n
. 
D
a
ta
 
A
n
a
ly
si
s 
n
/a
 
F
in
al
 c
o
d
es
 
w
er
e 
ap
p
li
ed
 t
o
 
d
o
cu
m
en
ts
 
u
si
n
g
 a
 
co
m
p
u
te
r-
iz
ed
 
q
u
al
it
at
iv
e 
p
ro
g
ra
m
 
(A
tl
as
.t
i)
, 
af
te
r 
w
h
ic
h
 
co
d
in
g
 
re
p
o
rt
s 
w
er
e 
p
ro
d
u
ce
d
 
fo
r 
ea
ch
 
g
lo
b
al
 
co
d
e.
 
C
o
d
in
g
 
g
ri
d
s 
w
er
e 
d
er
iv
ed
 
fr
o
m
 t
h
e 
re
p
o
rt
s 
to
 
id
en
ti
fy
 
p
ar
ti
ci
p
an
t 
ch
ar
ac
te
r-
is
ti
cs
. 
M
e
a
su
r
e
-
m
e
n
t 
S
T
D
 
in
fe
ct
io
n
 a
s 
o
b
je
ct
iv
e 
b
io
lo
g
ic
al
 
m
ar
k
er
s 
fo
r 
H
IV
 r
is
k
. 
In
te
rv
ie
w
s 
w
er
e 
tr
an
sc
ri
b
ed
 
an
d
 c
o
d
ed
 
fo
r 
g
lo
b
al
 
to
p
ic
s.
 
M
a
jo
r
 
V
a
ri
a
b
le
s 
P
rE
P
 
u
p
ta
k
e 
in
 
th
e 
U
S
 
h
as
 b
ee
n
 
lo
w
. 
 P
u
rv
ie
w
 
P
ar
ad
o
x
: 
w
h
o
 
sh
o
u
ld
 
p
ro
v
id
e 
P
rE
P
? 
(H
IV
 
sp
ec
ia
li
st
s 
v
s.
 P
C
P
s)
. 
S
a
m
p
le
/ 
S
e
tt
in
g
 
S
am
p
le
: 
n
/a
 
S
et
ti
n
g
: 
S
T
D
 
cl
in
ic
s 
N
 =
 3
0
 
p
ro
v
id
er
s:
 
2
4
 M
D
s,
 
4
 N
P
s,
 2
 
P
A
s.
 
S
et
ti
n
g
: 
g
re
at
er
 
N
ew
 
Y
o
rk
 
m
et
ro
-
p
o
li
ta
n
 
ar
ea
. 
D
e
si
g
n
/ 
M
e
th
o
d
 
C
o
m
m
en
ta
ry
 
 M
et
h
o
d
: 
su
m
m
ar
y
 o
f 
ev
id
en
ce
 r
eg
ar
d
in
g
 
P
rE
P
 e
ff
ic
ac
y
 a
n
d
 
h
ig
h
er
 r
is
k
 o
f 
H
IV
 
in
fe
ct
io
n
 r
el
at
ed
 t
o
 
S
T
D
 i
n
fe
ct
io
n
. 
M
o
d
el
s 
o
f 
P
rE
P
 
im
p
le
m
en
ta
ti
o
n
 i
n
 
S
T
D
 c
li
n
ic
s 
ar
e 
d
es
cr
ib
ed
. 
Q
u
al
it
at
iv
e 
st
u
d
y
 o
f 
in
te
rv
ie
w
 d
at
a.
 
M
et
h
o
d
: 
p
ra
ct
ic
in
g
 
cl
in
ic
ia
n
s 
w
h
o
 p
ro
v
id
e 
ca
re
 f
o
r 
M
S
M
, 
ID
U
s,
 &
 
h
ig
h
-r
is
k
 h
et
er
o
se
x
u
al
 
w
o
m
en
 w
er
e 
re
cr
u
it
ed
 
&
 p
ro
v
id
ed
 e
d
u
ca
ti
o
n
 
o
n
 P
rE
P
. 
E
x
te
n
si
v
e 
in
te
rv
ie
w
in
g
 (
1
-1
.5
 h
rs
) 
o
f 
ea
ch
 p
ar
ti
ci
p
an
t 
w
as
 
co
n
d
u
ct
ed
 b
y
 s
tu
d
y
 
co
in
v
es
ti
g
at
o
rs
 o
r 
p
ro
je
ct
 d
ir
ec
to
r 
ab
o
u
t 
th
e 
fo
ll
o
w
in
g
 t
o
p
ic
s:
 
P
rE
P
 k
n
o
w
le
d
g
e;
 
p
re
sc
ri
b
in
g
 g
u
id
el
in
es
; 
p
ri
o
r 
ex
p
er
ie
n
ce
 
p
re
sc
ri
b
in
g
 P
rE
P
; 
sk
il
ls
 
n
ee
d
ed
 t
o
 i
m
p
le
m
en
t 
P
rE
P
 i
n
 o
n
e’
s 
p
ra
ct
ic
e 
&
 a
n
ti
ci
p
at
ed
 
ch
al
le
n
g
es
; 
p
er
ce
p
ti
o
n
s 
o
f 
p
ee
rs
’ 
o
p
in
io
n
s 
o
f 
P
rE
P
; 
in
te
n
ti
o
n
s 
to
 
im
p
le
m
en
t 
P
rE
P
, 
&
 t
o
 
w
h
o
m
; 
an
ti
ci
p
at
ed
 
tr
ai
n
in
g
 n
ee
d
s;
 
p
re
fe
re
n
ce
s 
fo
r 
co
n
ti
n
u
in
g
 e
d
u
ca
ti
o
n
 
m
o
d
al
it
ie
s.
 
 
C
o
n
c
e
p
tu
a
l 
F
r
a
m
e
-
w
o
r
k
 
M
o
d
el
s 
o
f 
P
ra
ct
ic
e 
M
u
lt
i-
d
is
ci
p
li
n
-
ar
y
 
in
te
rv
ie
w
-
in
g
 
C
it
a
ti
o
n
 
H
o
o
v
er
, 
K
. 
W
.,
 H
am
, 
D
. 
C
.,
 P
et
er
s,
 P
. 
J.
, 
S
m
it
h
, 
D
. 
K
.,
 &
 B
er
n
st
ei
n
, 
K
. 
T
. 
(2
0
1
6
).
 H
u
m
an
 
im
m
u
n
o
d
ef
ic
ie
n
cy
 v
ir
u
s 
p
re
v
en
ti
o
n
 w
it
h
 
p
re
ex
p
o
su
re
 p
ro
p
h
y
la
x
is
 
in
 s
ex
u
al
ly
 t
ra
n
sm
it
te
d
 
d
is
ea
se
 c
li
n
ic
s.
 S
ex
u
a
ll
y 
T
ra
n
sm
it
te
d
 D
is
ea
se
s,
 
4
3
(5
),
 2
7
7
-2
8
2
. 
 
 H
o
ff
m
an
, 
S
.,
 G
u
id
ry
, 
J.
 
A
.,
 C
o
ll
ie
r,
 K
. 
L
.,
 
M
an
te
ll
, 
J.
 E
.,
 B
o
cc
h
er
-
L
at
ti
m
o
re
, 
D
.,
 
K
ai
g
h
o
b
ad
i,
 F
.,
 
&
 S
an
d
fo
rt
, 
T
. 
G
. 
(2
0
1
6
).
 A
 c
li
n
ic
al
 h
o
m
e 
fo
r 
p
re
ex
p
o
su
re
 
p
ro
p
h
y
la
x
is
: 
d
iv
er
se
 
h
ea
lt
h
 c
ar
e 
p
ro
v
id
er
s’
 
p
er
sp
ec
ti
v
es
 o
n
 t
h
e 
“P
u
rv
ie
w
 P
ar
ad
o
x
.”
 
Jo
u
rn
a
l 
o
f 
th
e 
In
te
rn
a
ti
o
n
a
l 
A
ss
o
ci
a
ti
o
n
 o
f 
P
ro
vi
d
er
s 
o
f 
A
ID
S
 C
a
re
, 
1
5
(1
),
 5
9
-
6
5
. 
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A
p
p
r
a
is
a
l 
M
et
a-
sy
n
th
es
is
 
L
im
it
at
io
n
s:
 
n
o
 
q
u
an
ti
ta
ti
v
e 
d
at
a 
as
 i
t 
w
as
 
a 
q
u
al
it
at
iv
e 
st
u
d
y
, 
b
u
t 
o
th
er
w
is
e 
th
o
ro
u
g
h
ly
 
as
su
re
d
 
in
te
rn
al
 
v
al
id
it
y
. 
S
tr
en
g
th
 o
f 
E
v
id
en
ce
: 
L
ev
el
 3
 
Q
u
al
it
y
 A
 
D
er
iv
at
io
n
: 
M
et
a-
sy
n
th
es
is
 
E
x
te
rn
al
 
v
al
id
at
io
n
: 
Q
u
as
i-
ex
p
er
im
en
ta
l 
st
u
d
y
. 
L
im
it
at
io
n
s:
 
q
u
al
it
at
iv
e 
d
at
a 
w
it
h
in
 v
ar
ia
b
le
s 
r/
t 
p
at
ie
n
t 
an
sw
er
s.
 H
ig
h
 
q
u
al
it
y
 d
at
a 
an
al
y
si
s:
 
m
u
lt
ip
le
 
so
ft
w
ar
e 
&
 
ap
p
ro
ac
h
es
 
as
su
re
d
 i
n
te
rn
al
 
&
 e
x
te
rn
al
 
v
al
id
it
y
. 
 
S
tr
en
g
th
 o
f 
 
E
v
id
en
ce
: 
 
L
ev
el
s 
3
 &
 2
 
Q
u
al
it
y
 A
 
F
in
d
in
g
s 
 
V
is
it
in
g
 a
 h
ea
lt
h
ca
re
 
p
ro
v
id
er
 i
n
 t
h
e 
p
as
t 
1
2
 m
o
, 
re
ce
iv
in
g
 a
n
 H
IV
 t
es
t 
fr
o
m
 a
 
p
ro
v
id
er
, 
an
d
 h
av
in
g
 a
n
 S
T
I 
te
st
 i
n
 t
h
e 
p
as
t 
1
2
 m
o
 w
er
e 
n
o
t 
si
g
n
if
ic
an
tl
y
 a
ss
o
ci
at
ed
 
w
it
h
 P
rE
P
 a
w
ar
en
es
s.
  
P
rE
P
 a
w
ar
en
es
s 
w
as
 
p
o
si
ti
v
el
y
 a
ss
o
ci
at
ed
 w
it
h
 
b
ei
n
g
 o
u
t 
to
 a
 h
ea
lt
h
ca
re
 
p
ro
v
id
er
 (
p
<
0
.0
0
1
);
 b
ei
n
g
 
te
st
ed
 f
o
r 
H
IV
 (
p
=
0
.0
2
3
);
 &
 
re
ce
iv
in
g
 c
o
n
d
o
m
s 
fr
o
m
 a
n
 
H
IV
/A
ID
S
 C
B
O
 (
p
=
0
.0
0
1
).
  
H
IV
 t
es
ti
n
g
 w
as
 s
ig
n
if
ic
an
tl
y
 
as
so
ci
at
ed
 w
/ 
m
o
st
 f
o
rm
s 
o
f 
h
ea
lt
h
ca
re
 c
o
n
ta
ct
. 
 
H
ea
lt
h
ca
re
 p
ro
v
id
er
s 
ar
e 
p
ro
v
id
in
g
 H
IV
 t
es
ti
n
g
 t
o
 
M
S
M
, 
b
u
t 
n
o
t 
P
rE
P
. 
F
in
al
 D
en
v
er
 H
IV
 r
is
k
 s
co
re
 
in
cl
u
d
ed
 p
re
d
ic
ti
v
e 
v
ar
ia
b
le
s:
 
ag
e,
 g
en
d
er
, 
ra
ce
/e
th
n
ic
it
y
, 
se
x
 w
/ 
a 
m
al
e,
 v
ag
in
al
 
in
te
rc
o
u
rs
e,
 r
ec
ep
ti
v
e 
an
al
 
in
te
rc
o
u
rs
e,
 I
D
U
, 
&
 p
as
t 
H
IV
 t
es
ti
n
g
. 
 
H
IV
 p
re
v
al
en
ce
 f
o
r 
th
e 
fo
ll
o
w
in
g
 s
co
re
s:
 
<
2
0
: 
0
.3
1
%
 
2
0
-2
9
: 
0
.4
1
%
 
3
0
-3
9
: 
0
.9
9
%
 
4
0
-4
9
: 
1
.5
9
%
 
5
0
 a
n
d
 u
p
: 
3
.5
9
%
 (
9
5
%
 C
I 
ea
ch
).
 
D
en
v
er
 H
IV
 r
is
k
 s
co
re
 
ac
cu
ra
te
ly
 c
at
eg
o
ri
ze
s 
p
at
ie
n
ts
 i
n
to
 g
ro
u
p
s 
w
it
h
 
in
cr
ea
si
n
g
 p
ro
b
ab
il
it
ie
s 
o
f 
H
IV
 i
n
fe
ct
io
n
. 
D
a
ta
 A
n
a
ly
si
s 
S
ta
ta
, 
v
er
si
o
n
 1
2
, 
w
as
 
u
se
d
 t
o
 c
o
n
d
u
ct
 a
n
al
y
se
s:
 
as
so
ci
at
io
n
s 
b
et
w
ee
n
 
h
ea
lt
h
ca
re
 c
o
n
ta
ct
s 
an
d
 
P
rE
P
 a
w
ar
en
es
s 
w
er
e 
es
ti
m
at
ed
 v
ia
 l
o
g
is
ti
c 
re
g
re
ss
io
n
 m
o
d
el
s 
co
n
tr
o
ll
in
g
 f
o
r 
ag
e,
 r
ac
e 
an
d
 e
d
u
ca
ti
o
n
, 
an
d
 
cl
u
st
er
in
g
 b
y
 v
en
u
e.
 
A
d
d
it
io
n
al
 c
o
m
p
ar
at
iv
e 
an
al
y
se
s 
b
et
w
ee
n
 P
rE
P
 
an
d
 o
th
er
 H
IV
 p
re
v
en
ti
o
n
 
in
te
rv
en
ti
o
n
 w
er
e 
co
n
d
u
ct
ed
 w
it
h
 H
IV
 
te
st
in
g
 a
s 
an
 o
u
tc
o
m
e.
 
H
ea
lt
h
ca
re
 p
ro
v
id
er
 a
n
d
 
C
B
O
 c
o
n
ta
ct
 r
eg
ar
d
in
g
 
H
IV
 t
es
ti
n
g
 i
n
 t
h
e 
p
as
t 
y
ea
r 
w
as
 e
v
al
u
at
ed
. 
L
as
tl
y
, 
st
at
is
ti
ca
l 
an
al
y
si
s 
w
as
 c
o
n
d
u
ct
ed
. 
D
er
iv
at
io
n
: 
D
en
v
er
 H
IV
 r
is
k
 
m
o
d
el
 d
ev
el
o
p
m
e
n
t:
 m
u
lt
i-
v
ar
ia
b
le
 l
o
g
is
ti
c 
re
g
re
ss
io
n
, 
b
iv
ar
ia
te
 s
ta
ti
st
ic
al
 t
es
ti
n
g
, 
A
k
ai
k
e’
s 
In
fo
rm
at
io
n
 
C
ri
te
ri
o
n
 f
o
r 
g
lo
b
al
 t
es
t 
o
f 
g
o
o
d
 f
it
, 
st
at
is
ti
ca
l 
an
al
y
si
s 
o
f 
p
re
d
ic
ti
v
e 
ab
il
it
y
 o
f 
v
ar
ia
b
le
s.
 I
n
te
rn
al
 v
al
id
it
y
: 
1
0
-f
o
ld
 c
ro
ss
- 
v
al
id
at
io
n
 &
 
ca
li
b
ra
ti
o
n
 b
y
 g
ra
p
h
ic
al
ly
 
co
m
p
ar
in
g
 p
re
d
ic
te
d
 H
IV
 
p
re
v
al
en
ce
 w
/ 
o
b
se
rv
ed
 H
IV
 
p
re
v
al
en
ce
. 
E
x
te
rn
al
 v
al
id
it
y
: 
d
at
a 
m
an
ag
ed
 w
/ 
M
ic
ro
so
ft
 
A
cc
es
s.
 S
ta
ti
st
ic
al
 a
n
al
y
se
s:
 
S
A
S
, 
v
er
si
o
n
 9
.2
; 
S
ta
ta
, 
v
er
si
o
n
 1
0
.1
; 
S
P
S
S
, 
v
er
si
o
n
 
1
8
. 
M
ar
k
o
v
 c
h
ai
n
 M
o
n
te
 
C
ar
lo
 a
p
p
ro
ac
h
 -
 t
o
 p
ro
m
o
te
 
v
al
id
it
y
 o
f 
re
su
lt
s.
 
B
o
o
ts
tr
ap
p
in
g
 a
p
p
ro
ac
h
 t
o
 
es
ti
m
at
e 
9
5
%
 C
I 
fo
r 
re
g
re
ss
io
n
 c
o
ef
fi
ci
e
n
ts
 o
f 
fi
n
al
 m
o
d
el
. 
  
M
e
a
su
r
e
m
e
n
t 
E
x
p
o
su
re
s 
to
 h
ea
lt
h
ca
re
 
v
s 
C
B
O
 c
o
n
ta
ct
s:
 
1
. 
S
ee
in
g
 a
 h
ea
lt
h
ca
re
 
p
ro
v
id
er
 i
n
 t
h
e 
p
as
t 
1
2
 
m
o
; 
2
.H
av
in
g
 a
 u
su
al
 
so
u
rc
e 
o
f 
ca
re
; 
3
.B
ei
n
g
 
o
u
t 
to
 a
 h
ea
lt
h
ca
re
 
p
ro
v
id
er
; 
4
.R
ec
ei
v
in
g
 
H
IV
 t
es
ti
n
g
 f
ro
m
 
h
ea
lt
h
ca
re
 p
ro
v
id
er
; 
5
.G
et
ti
n
g
 t
es
te
d
 f
o
r 
H
IV
; 
6
.G
et
ti
n
g
 t
es
te
d
 f
o
r 
S
T
I;
 
7
.T
es
ti
n
g
 p
o
si
ti
v
e 
fo
r 
an
 
S
T
I;
 8
.P
ar
ti
ci
p
at
in
g
 i
n
 
in
d
iv
id
u
al
 H
IV
 
p
re
v
en
ti
o
n
 c
o
u
n
se
li
n
g
; 
9
.P
ar
ti
ci
p
at
in
g
 i
n
 g
ro
u
p
 
H
IV
 p
re
v
en
ti
o
n
 
co
u
n
se
li
n
g
; 
1
0
.R
ec
ei
v
in
g
 
fr
ee
 c
o
n
d
o
m
s 
fr
o
m
 a
n
 
H
IV
 C
B
O
; 
1
1
. 
R
ec
ei
v
in
g
 
fr
ee
 c
o
n
d
o
m
s 
fr
o
m
 a
n
 
L
G
B
T
 C
B
O
. 
P
re
d
ic
ti
v
e 
v
al
u
e 
o
f 
v
ar
ia
b
le
s;
 p
re
d
ic
ti
v
e 
ab
il
it
y
 o
f 
D
en
v
er
 H
IV
 
ri
sk
 s
co
re
 m
o
d
el
; 
p
re
d
ic
ti
v
e 
H
IV
 
p
re
v
al
en
ce
 v
s 
o
b
se
rv
ed
 
H
IV
 p
re
v
al
en
ce
. 
M
a
jo
r
 
V
a
ri
a
b
le
s 
P
rE
P
 
aw
ar
en
es
s 
re
la
te
d
 t
o
 
h
ea
lt
h
ca
re
 v
s 
C
B
O
 
co
n
ta
ct
s.
 
D
em
o
g
ra
p
h
ic
 
ch
ar
ac
te
r-
is
ti
cs
, 
sy
m
p
to
m
s,
 
S
T
I 
h
x
, 
se
x
u
al
 
h
x
, 
sp
ec
if
ic
 
se
x
u
al
 
p
ra
ct
ic
es
 &
 
co
n
d
o
m
 u
se
, 
g
en
d
er
 o
f 
se
x
u
al
 
co
n
ta
ct
s,
 
p
re
v
io
u
s 
H
IV
 
te
st
in
g
 h
x
, 
o
th
er
 r
is
k
 
fa
ct
o
rs
 f
o
r 
H
IV
 
tr
an
sm
is
si
o
n
. 
C
o
n
fi
rm
ed
 
H
IV
 i
n
fe
ct
io
n
 
se
rv
ed
 a
s 
th
e 
o
u
tc
o
m
e/
 
d
ep
en
d
en
t 
v
ar
ia
b
le
. 
S
a
m
p
le
/ 
S
e
tt
in
g
 
N
 =
 4
0
1
 
M
S
M
 
 S
et
ti
n
g
: 
2
0
1
4
 
B
al
ti
m
o
re
 
N
H
B
S
 
d
at
a.
 
D
er
iv
a-
ti
o
n
 
sa
m
p
le
: 
9
2
,6
3
5
, 
o
f 
w
h
ic
h
 5
0
4
 
H
IV
-p
o
s.
  
S
et
ti
n
g
: 
D
en
v
er
 
M
et
ro
 
H
ea
lt
h
 
C
li
n
ic
 
(S
T
D
 
cl
in
ic
).
 
V
al
id
at
io
n
 
sa
m
p
le
: 
2
2
,9
8
3
  
  
 
S
et
ti
n
g
: 
U
n
iv
er
si
ty
 
o
f 
C
in
ci
n
n
at
i 
M
ed
ic
al
 
C
en
te
r 
E
R
. 
D
e
si
g
n
/ 
M
e
th
o
d
 
 Q
u
al
it
at
iv
e 
d
at
a 
an
al
y
si
s 
 M
et
h
o
d
: 
d
at
a 
fr
o
m
 t
h
e 
2
0
1
4
 
M
S
M
 w
av
e 
o
f 
N
at
io
n
al
 H
IV
 
B
eh
av
io
ra
l 
S
u
rv
ei
ll
an
ce
 
(N
H
B
S
) 
in
 
B
al
ti
m
o
re
 w
er
e 
co
ll
ec
te
d
 a
n
d
 
an
al
y
ze
d
 f
o
r 
ex
p
o
su
re
s 
to
 
h
ea
lt
h
ca
re
 v
er
su
s 
co
m
m
u
n
it
y
 
b
as
ed
 
o
rg
an
iz
at
io
n
 
(C
B
O
) 
co
n
ta
ct
s 
an
d
 P
rE
P
 
aw
ar
en
es
s.
 
S
cr
ee
n
in
g
 t
o
o
l 
d
ev
el
o
p
m
en
t;
 
in
te
rn
al
 &
 
ex
te
rn
al
 
v
al
id
at
io
n
. 
M
et
h
o
d
: 
D
en
v
er
 
H
IV
 r
is
k
 s
co
re
 
d
er
iv
ed
 f
ro
m
 
an
al
y
si
s 
o
f 
p
ro
sp
ec
ti
v
el
y
 
co
ll
ec
te
d
 d
at
a 
fr
o
m
 r
o
u
ti
n
e 
as
se
ss
m
en
t 
p
at
ie
n
t 
in
fo
rm
at
io
n
 
re
q
u
ir
ed
 f
o
r 
H
IV
 
te
st
in
g
, 
p
ro
d
u
ci
n
g
 
H
IV
 r
is
k
 
p
re
d
ic
ti
o
n
 m
o
d
el
. 
In
te
rn
al
 v
al
id
it
y
 
es
ta
b
li
sh
ed
, 
th
en
 
ex
te
rn
al
ly
 t
es
te
d
 
at
 a
 d
if
fe
re
n
t 
h
ea
lt
h
ca
re
 s
it
e 
in
 
an
o
th
er
 s
ta
te
. 
C
o
n
c
e
p
tu
a
l 
F
r
a
m
e
-
w
o
r
k
 
D
is
se
m
in
-
at
io
n
 o
f 
P
rE
P
 
aw
ar
en
es
s 
H
IV
 r
is
k
 
sc
re
en
in
g
 
to
o
l 
C
it
a
ti
o
n
 
R
ai
fm
an
, 
J.
 R
.,
 
F
ly
n
n
, 
C
.,
 &
 
G
er
m
an
, 
D
. 
(2
0
1
7
).
 
H
ea
lt
h
ca
re
 
p
ro
v
id
er
 c
o
n
ta
ct
 
an
d
 p
re
-
ex
p
o
su
re
 
p
ro
p
h
y
la
x
is
 i
n
 
B
al
ti
m
o
re
 m
en
 
w
h
o
 h
av
e 
se
x
 
w
it
h
 m
en
. 
A
m
er
ic
a
n
 
Jo
u
rn
a
l 
o
f 
P
re
ve
n
ta
ti
ve
 
M
ed
ic
in
e,
 5
2
(1
),
 
5
5
-6
3
. 
 
 H
au
k
o
o
s,
 J
. 
S
.,
 
L
y
o
n
s,
 M
. 
S
.,
 
L
in
d
se
ll
, 
C
. 
J.
, 
H
o
p
k
in
s,
 E
.,
 
B
en
d
er
, 
B
.,
 
R
o
th
am
, 
R
. 
E
.,
 
…
 B
y
y
n
y
, 
R
. 
L
. 
(2
0
1
1
).
 
D
er
iv
at
io
n
 a
n
d
 
v
al
id
at
io
n
 o
f 
th
e 
D
en
v
er
 h
u
m
an
 
im
m
u
n
o
d
ef
ic
ie
n
cy
 v
ir
u
s 
(H
IV
) 
ri
sk
 s
co
re
 f
o
r 
ta
rg
et
ed
 H
IV
 
sc
re
en
in
g
. 
A
m
er
ic
a
n
 
Jo
u
rn
a
l 
o
f 
E
p
id
em
io
lo
g
y,
 
1
7
5
(8
),
 8
3
8
-
8
4
6
. 
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A
p
p
ra
is
a
l 
M
et
a-
sy
n
th
es
is
 
 L
im
it
at
io
n
s:
 n
o
 
tr
ia
l 
to
 a
ss
es
s 
im
p
le
m
en
ta
ti
o
n
 
o
f 
H
IR
I-
M
S
M
. 
L
ac
k
s 
ex
te
rn
al
 
v
al
id
it
y
 
 S
tr
en
g
th
 o
f 
 
E
v
id
en
ce
: 
L
ev
el
 3
 
 Q
u
al
it
y
 A
 
F
in
d
in
g
s 
 
F
in
al
 l
o
g
is
ti
c 
re
g
re
ss
io
n
 m
o
d
el
 
fo
r 
H
IR
I-
M
S
M
 
in
cl
u
d
ed
: 
A
g
e;
 
D
u
ri
n
g
 p
as
t 
6
 m
o
: 
T
o
ta
l 
#
 o
f 
m
al
e 
se
x
 
p
ar
tn
er
s;
 t
o
ta
l 
#
 o
f 
H
IV
-p
o
si
ti
v
e 
m
al
e 
se
x
 p
ar
tn
er
s;
 
n
u
m
b
er
 o
f 
ti
m
es
 o
f 
u
n
p
ro
te
ct
ed
 
re
ce
p
ti
v
e 
an
al
 s
ex
 
w
/ 
 a
 m
al
e 
p
ar
tn
er
 
o
f 
an
y
 H
IV
 s
ta
tu
s;
 
N
u
m
b
er
 o
f 
ti
m
es
 o
f 
in
se
rt
iv
e 
an
al
 s
ex
 
w
/ 
an
 H
IV
-p
o
si
ti
v
e 
m
al
e 
p
ar
tn
er
; 
u
se
 
o
f 
p
o
p
p
er
s;
 u
se
 o
f 
am
p
h
et
am
in
es
. 
 A
re
a 
u
n
d
er
 R
O
C
 
cu
rv
e:
 0
.7
4
 
 In
d
ex
 s
co
re
s 
ra
n
g
e 
fr
o
m
 0
-4
7
 
S
co
re
 o
f 
1
0
 &
 u
p
 
h
as
 s
en
si
ti
v
it
y
 o
f 
8
4
%
 &
 s
p
ec
if
ic
it
y
 
o
f 
4
5
%
, 
le
v
el
s 
ap
p
ro
p
ri
at
e 
fo
r 
a 
sc
re
en
in
g
 t
o
o
l.
 
D
a
ta
 A
n
a
ly
si
s 
G
en
er
al
iz
ed
 e
st
im
at
in
g
 
eq
u
at
io
n
s 
w
er
e 
u
se
d
 t
o
 f
it
 
lo
g
is
ti
c 
re
g
re
ss
io
n
 
m
o
d
el
s 
to
 a
d
ju
st
 f
o
r 
o
v
er
-
ti
m
e 
co
rr
el
at
io
n
 i
n
 
v
ar
ia
b
le
s.
  
S
ta
ti
st
ic
al
 a
n
al
y
si
s 
o
f 
p
re
d
ic
ti
v
e 
ab
il
it
y
 o
f 
ea
ch
 
v
ar
ia
b
le
. 
B
o
o
ts
tr
ap
 a
n
d
 b
ac
k
w
ar
d
 
el
im
in
at
io
n
 p
ro
ce
d
u
re
 
w
er
e 
u
se
d
 t
o
 s
el
ec
t 
v
ar
ia
b
le
s 
fo
r 
th
e 
fi
n
al
 
m
o
d
el
, 
w
h
ic
h
 i
n
cl
u
d
ed
 
o
n
ly
 t
h
o
se
 w
it
h
 P
<
0
.0
5
 
st
at
is
ti
ca
l 
si
g
n
if
ic
an
ce
. 
M
u
lt
ip
li
ca
ti
o
n
 o
f 
re
g
re
ss
io
n
 c
o
ef
fi
ci
en
ts
 
fo
r 
ea
ch
 b
y
 1
0
 a
n
d
 
ro
u
n
d
ed
 t
o
 t
h
e 
n
ea
re
st
 
in
te
g
er
 w
as
 c
o
n
d
u
ct
ed
 t
o
 
d
ev
el
o
p
 p
o
in
t 
sc
o
re
s 
fo
r 
th
e 
in
d
ex
. 
P
o
in
t 
v
al
u
es
 
fo
r 
al
l 
v
ar
ia
b
le
s 
in
 t
h
e 
m
o
d
el
 w
er
e 
su
m
m
ed
 t
o
 
es
ta
b
li
sh
 a
 h
ig
h
-r
is
k
 
M
S
M
 i
n
d
ex
 s
co
re
. 
 
D
if
fe
re
n
t 
sc
o
re
 c
u
t-
o
ff
s 
es
ta
b
li
sh
ed
 b
y
 c
o
m
p
u
ti
n
g
 
se
n
si
ti
v
it
y
, 
sp
ec
if
ic
it
y
, 
an
d
 a
re
a 
u
n
d
er
 R
O
C
 
cu
rv
e.
  
 
M
ea
su
re
-
m
en
t 
P
re
d
ic
ti
v
e 
ab
il
it
y
 o
f 
v
ar
ia
b
le
s 
M
a
jo
r 
V
a
ri
a
b
le
s 
A
g
e 
 In
 p
as
t 
6
 m
o
n
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Appendix F 
Statement of Determination  
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Statement of Determination (continued) 
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Statement of Determination (continued) 
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Appendix G 
HIV PrEP Screening Tool Implemented into the EHR  
 
*Note: Highlighted answers indicate HIV risk and PrEP offer/discussion of PrEP 
 
 
 
 
 
 
 
 
 
 
HIV PREP   56 
 
Appendix H 
Clinical Support Tools Implemented into the EHR  
PrEP order set linked to STI-related ICD-10 diagnoses: 
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Clinical Support Tools Implemented into the EHR (continued) 
PrEP evaluation progress note template: 
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Appendix I 
Clinical Staff Post-Education Tests 
Medical Assistant Test: 
HIV Risk Screening Protocol 
1. Which of the following are signs that indicate eligibility for PrEP? (Highlight all that 
apply) 
□ Recent STI diagnosed in the past 6 months 
□ Current STI diagnosis 
□ 80% condom use for vaginal and/or anal sexual intercourse 
□ Illicit drug use 
□ Multiple sexual partners of known HIV -negative status 
□ Multiple sexual partners with 100% condom use 
□ Monogamous relationship with HIV-positive sexual partner 
□ Injection drug use without equipment sharing and uses clean needles only 
□ History of syphilis from 10 years ago 
□ Monogamous relationship with HIV-negative partner  
□ HIV-negative injecting partner 
□ Exchanges sex for rent  
□ Transgender woman who is asexual  
□ HIV-positive injecting partner 
2. True or False: At the end of the sexual health assessment, always ask the patient if they 
have heard of PrEP. (Highlight answer) 
a. True 
b. False 
3. After conducting the sexual health assessment, what do you do next? (Highlight answer) 
a. Report results of the patient’s sexual health assessment to the provider at huddle. 
b. State whether or not the patient is eligible for PrEP and ask the provider to discuss 
PrEP with the patient.  
c. Both a & b  
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Clinical Staff Post-Education Tests (continued) 
Provider Test Part 1: 
HIV Risk Screening Protocol 
1. Which of the following are signs that indicate eligibility for PrEP? (Highlight all that 
apply) 
□ Recent STI diagnosed in the past 6 months 
□ Current STI diagnosis 
□ 80% condom use for vaginal and/or anal sexual intercourse 
□ Injected drug use 
□ Multiple sexual partners of known HIV -negative status 
□ Multiple sexual partners with 100% condom use 
□ Monogamous relationship with HIV-positive sexual partner 
□ Injection drug use without equipment sharing and uses clean needles only 
□ History of syphilis from 10 years ago 
□ Monogamous relationship with HIV-negative partner  
□ HIV-negative injecting partner 
□ Exchanges sex for rent  
□ Transgender woman who denies sexual activity in the last 12 months 
□ HIV-positive injecting partner 
2. True or False: At the end of the sexual health assessment, always ask the patient if they 
have heard of PrEP, unless they are already on PrEP. (Highlight answer) 
a. True 
b. False 
3. After a patient’s STI test result comes back positive, what do you do next? (Highlight 
answer) 
a. Treat the STI 
b. Discuss PrEP (and document) 
c. Both a & b  
4. What is the purpose of integrating the sexual health assessment with PrEP eligibility 
screening? (Highlight answer) 
a. To make using ECW more complicated to use. 
b. To identify PrEP eligible patients. 
c. To ultimately increase PrEP uptake among patients at risk for acquiring HIV 
infection.  
d. b & c 
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Clinical Staff Post-Education Tests (continued) 
Provider Test Part 2: 
Clinical Decision Support Tool: Triggered PrEP Order Set 
1. True or False: When sexual health risk related ICD-10 diagnoses codes are entered, the 
PrEP evaluation order set will be triggered. (Highlight answer) 
a. True 
b. False 
 
2. How do you access the triggered PrEP evaluation order set? (Highlight answer) 
a. Do nothing, it will automatically appear. 
b. Click on the “stop sign” button that will turn red on the upper right corner of the 
ECW screen.  
c. Enter each order for PrEP evaluation individually. 
3. Where is the “stop sign” button for accessing triggered order sets located? (Highlight 
answer) 
a. It will pop up in the center of the ECW screen. 
b. It will turn green in the left corner of the ECW screen.  
c. It will turn red in the right corner of the ECW screen. 
4. What is the purpose of the triggered PrEP order set? (Highlight answer) 
a. To make ordering everything required for PrEP evaluation easier and more 
streamlined.  
b. To make ECW more complicated to use. 
c. To ultimately increase PrEP uptake among patients at risk for acquiring HIV 
infection.  
d. Both a & c 
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Appendix J 
Gap Analysis 
 
 
 
 
 
Inconsistent 
clinical practice 
of HIV risk 
screening. 
 
No standardized 
practice for PrEP 
implementation. 
 
Standardized 
process for HIV 
risk screening 
and PrEP 
implementation. 
 
100% of patients 
at risk for 
acquiring HIV 
are identified 
and offered PrEP 
for HIV 
prevention. 
48% of patients 
with history of 
sexual HIV risk 
are offered 
PrEP. 
 
35% of patients 
tested positive 
for an STI are 
offered PrEP. 
 
*Note: See baseline 
clinical data 
assessment in 
Appendix C 
 
Lack of 
standardization 
of clinical 
practice that 
specifies routine 
health 
screenings to be 
conducted for 
the type patient 
encounter. 
 
Provider 
preference on 
which clinical 
staff performs 
routine health 
screenings: 
providers vs. 
MAs. 
 
High rate of 
clinical staff 
turnover. 
Standardized 
screening tool 
for sexual 
history 
assessment and 
HIV risk.  
 
Standardized 
HIV risk 
screening 
protocol that 
utilizes 
screening tool 
for specified 
patient 
encounters. 
 
 
 
 
 
 
 
Current 
Situation  
Future 
Situation/ 
Goal  
Gaps Factors Remedies  
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Appendix K 
Gantt Chart 
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Appendix L 
SWOT Analysis 
Strengths 
• Compassionate and culturally 
sensitive environment 
• Small organizational size 
• FQHC status 
• Patient population represents at-risk 
population eligible for PrEP 
• Chief medical officer and lead 
provider support 
Weaknesses 
• No standardized protocols 
• Many changes to clinic workflow 
• Outdated EHR 
• High rate of clinical staff turnover 
Opportunities 
• At-risk patient population 
• FQHC status: more primary care 
patients 
• Screening tool implementation using 
EHR system potentially contributes to 
meaningful use for possible future 
HIV prevention standard 
• Improve patient outcomes in HIV 
prevention 
• Implications for public health safety: 
Getting to Zero San Francisco 
Threats 
• Patient refusal of PrEP 
• Cultural stigma 
• Financial cost of PrEP 
• Low HIV risk perception 
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Appendix M 
DNP Project Cost Summary  
Costs Absorbed into the Asian and Pacific Islander Wellness Center FTE Budget 
API staff member  Estimated hourly 
wage (FTE)1 
Number of hours 
spent on project 
Subtotal cost (FTE)  
CMO/Physican $93.48 2 $280.44 
Lead NP  $71.61 20 $1,432.20 
Volunteer Nurse 
Practitioner  
$0 0.33  
(20 min) 
$0 
Medical Assistant (4) $31.66 0.33 
(20 min) 
$41.79 
Director of Nursing $67.00 0.33 
(20 min) 
$22.11 
PrEP Case Manager $30.00 1 $30.00 
EHR System 
Consultant 
$55.00 2 $110.00 
Clinical Data 
Specialist 
$30 8 $240.00 
DNP Author/Project 
Manager 
$0 163 $0 
Estimated cost of DNP project  $2,156.54 
Cost for Primary Care Clinics to Implement HIV Risk Screening Protocol 
Staff leader for 
implementation  
Estimated hourly 
wage of project 
manager (FTE)2 
Number of hours 
anticipated to be 
spent on project 
implementation 
Subtotal cost (FTE) 
Project Manager $42.52 100 $4,252.00 
Estimated cost of for primary care clinics 
Clinical staff costs ($2,156.54) + project manager  
$6,408.54 
1API staff wage estimates from equivalent City and County of San Francisco public health job listings. Retrieved from 
http://www.jobaps.com/SF/ 
2Project manager wage estimate based on average salary for project manager consultant in San Francisco reported by Glassdoor. 
Retrieved from https://www.glassdoor.com/Salaries/project-management-consultant-salary-SRCH_KO0,29.htm 
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DNP Project Cost Summary (continued) 
 
Cost-Avoidance Estimate 
HIV management costs $20,000+ per patient per year1 
Estimated HIV management costs for the 
reported 16,002 people living with HIV in San 
Francisco at the end of 20152 
Estimated cost of $320,040,000 spent in 2015 
if every person was on HIV antiretroviral 
treatment 
Estimated total cost of HIV management if all 
232 patients suspected at-risk acquired HIV 
infection3 
A minimum of $4,640,000 per year 
Cost of PrEP $13,000 per patient per year1 
Estimated total cost of PrEP for all 232 
patients suspected at risk for HIV acquisition3 
$3,016,000 per year 
Estimated cost avoidance by starting all 232 
suspected at-risk patients on PrEP3 
A minimum of $1,624,000 per year 
 
1Centers for Disease Control and Prevention. (2015). HIV cost effectiveness. Retrieved from 
http://www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html 
2San Francisco Department of Public Health. (2015). HIV Semi-annual surveillance seport. Retrieved from 
https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/HIV-SemiAnnualReport122015.pdf  
3 Estimated number of at-risk patients based on approximate 2016 unique patient census of 381 as reported by API’s clinical data 
specialist (C. Ong-Flaherty, personal communication, April 5, 2017).  
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Appendix N 
Budget Return on Investment Plan 
Medi-Cal reimbursement rate to API: $25 per patient per month per year1 
Percentage of patients at risk for HIV 
acquisition 
61%2 
Approximate total number of patients  
at end of 2016 
3813 
Estimated number of patients suspected at 
risk for acquiring HIV 
232 
 
Medi-Cal reimbursement estimate if all at-risk patients are new to care and Medi-Cal coverage 
are started on PrEP: 
232 patients x $25 x 12 months per year= $69,600 in one year 
 
*Note: Estimate based on assumption that the 232 at-risk patients are new to care and Medi-Cal coverage. Established Medi-Cal 
patients who initiate PrEP would not produce additional reimbursement cash flow, but for PrEP follow-up would keep them in 
care, contributing to patient and reimbursement retention. Minimal reimbursement estimate. Does not include other health 
insurance plan reimbursement rates.  
1 Per API’s CMO. (T. Do, personal communication, May 9, 2016). 
2 Based on baseline clinical data assessment. 
3 Based on approximate 2016 unique patient census as reported by API’s clinical data specialist (C. Ong-Flaherty, personal 
communication, April 5, 2017).  
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Appendix O 
Work Breakdown Structure by Person 
Stakeholder Project Role Item/Event Special Instructions 
Dr. Tri Do 
Chief medical officer 
API physician 
Authorization 
 
Change in practice 
approval 
 
Review and approve project and 
screening tool intervention 
DNP co-chairs: Drs. 
Chenit Ong-Flaherty and 
Prabjot Sandhu 
DNP committee: Dr. 
Stefan Rowniak 
 
Authorization, guidance, 
critique and assessment of 
implementation and 
evaluation. 
DNP project 
approval 
 
Assist and support with 
development and approval of 
DNP project. 
Dr. Blair Turner 
Lead NP  
Supervision and guidance 
of project 
 
Change in practice: 
HIV risk screening 
protocol 
 
Provide supervision, assistance, 
and support for development of 
project. 
DNP author/Project 
manager: Cara Nalagan 
 
Project developer, 
manager, and evaluator  
 
Change in practice:  
HIV risk screening 
protocol 
Develop, implement, and 
evaluate HIV risk screening 
protocol to optimize PrEP 
implementation. 
EHR system consultant, 
clinical data specialist and 
USF health informatics 
student intern 
 
EHR system navigation 
 
Baseline clinical 
data assessment, 
electronic 
screening tool  
Assist with using EHR system to 
conduct baseline clinical data 
assessment, and with 
development of screening tool 
into the EHR. 
PrEP case manager Intervention design Change in practice Provide input for designing 
appropriate HIV risk screening 
protocol. 
Gilead Sciences assistant 
director of medical 
sciences for the west 
coast region, and local 
representative 
Intervention design Change in practice Provide input for designing 
appropriate HIV risk screening 
protocol. 
San Francisco City Clinic 
and Strut PrEP program 
managers 
Intervention design Change in practice Provide input for designing 
appropriate HIV risk screening 
protocol. 
City Wide PrEP NP Intervention design, 
clinical staff education, 
and potential 
dissemination 
Change in practice Provide input for designing 
appropriate HIV risk screening 
protocol, assist with clinical staff 
education, and potentially 
disseminate protocol to other 
primary care clinics in SF.  
Clinic providers and staff 
(MD, NPs, RNs, MAs, 
clinic operations manager, 
director of nursing) 
 
Intervention recipients 
 
Change in practice 
 
Learn and follow HIV risk 
screening protocol to increase 
identification of patients at risk 
for acquiring HIV and increase 
provider offer of PrEP. 
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Appendix P 
Communication Plan by Item/Event 
Item/Event Purpose Audience Date/ 
Frequency 
Who is 
Responsible 
Authority & 
Release 
Brainstorm Develop 
appropriate HIV 
risk screening 
protocol 
 
Dr. Turner, 
DNP 
committee, 
Gilead Sciences 
support 
representatives, 
San Francisco 
City Clinic and 
Strut PrEP 
managers, City 
Wide PrEP NP,  
PrEP case 
manager, and 
the author 
May 31, 2016 to 
September 6, 
2016 
 
The author and 
Dr. Turner 
 
 
Dr. Turner (lead 
NP) and Dr. Do 
(CMO)  
 
EHR system 
navigation 
 
Baseline clinical 
data assessment,  
Development of 
HIV PrEP 
screening tool in 
the EHR system 
 
Dr. Turner and 
the author 
 
August 7, 2016 
to September 6, 
2016 
 
Clinical data 
specialist, EHR 
system 
consultant, Dr. 
Turner, and the 
author 
Dr. Turner (lead 
NP) and Dr. Do 
(CMO)  
 
Implementation 
of HIV risk 
screening 
protocol 
 
Increase 
identification of 
patients at risk 
for acquiring 
HIV and 
increase 
provider offer of 
PrEP. 
Clinical staff & 
providers 
 
October 16, 
2016 to 
February 1, 
2017 
 
The author and 
Dr. Turner 
 
Dr. Turner (lead 
NP) and Dr. Do 
(CMO)  
 
Evaluation 
 
Evaluate 
effectiveness of 
intervention 
 
Clinical staff 
and providers 
January 9, 2017 
to February 5, 
2017 
 
The author  Dr. Turner (lead 
NP) and Dr. Do 
(CMO)  
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Appendix Q 
Authorization 
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Appendix R 
Evaluation Plan 
Deadline  Evaluation Method 
October 23, 2016 Clinical staff comprehension 
of HIV risk identification and 
screening tool use 
Screening tool post-education 
test with a passing score of 
80% 
February 1, 2017 Clinical staff compliance rate 
of 80% for routine screening 
tool use 
Retrieve clinical data from 
the EHR system and use 
Microsoft Excel to calculate 
the percentage of screening 
tool use per STI testing, 
establish new patient, and 
annual physical exam patient 
encounter  
February 1, 2017 An increase by 50% in PrEP 
offer for patients with sexual 
HIV risk, and for patients 
tested positive for an STI 
compared to baseline 
 
An increase by 50% in PrEP 
evaluation for patients offered 
PrEP, and in PrEP uptake for 
eligible patients compared to 
baseline 
As evidenced by the data 
captured by the screening tool 
and by individual chart 
reviews in the EHR and 
analyzed in Microsoft Excel 
by calculating percentages 
and generating graphs, 
repeated in a similar method 
used in the baseline clinical 
data assessment 
February 5, 2017 HIV risk screening protocol  Complete evaluations and 
summarize results using 
Microsoft Excel to calculate 
percentages and generate 
graphs to compare baseline 
and post-intervention results 
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Appendix S 
Results of Primary Outcomes 
1. Baseline: 48% of patients identified with sexual HIV risk were offered PrEP. 
Target: 72% 
Post-intervention: 81% of patients identified with sexual HIV risk were offered PrEP.  
 
 
2. Baseline: 35% of patients tested positive for an STI were offered PrEP. 
Target: 53% 
Post-intervention: 56% of patients tested positive for an STI were offered PrEP. 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Baseline Post Intervention
Percentage of patients with sexual HIV risk who 
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PrEP Offered
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who were offered PrEP
PrEP Offer s/p STI Dx
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Results of Primary Outcomes (continued) 
3. Baseline: 35% of patients offered PrEP completed PrEP evaluation. 
Target: 53% 
Post-intervention: 56% of patients offered PrEP completed PrEP evaluation. 
 
 
 
4. Baseline: 28% of patients evaluated as eligible for PrEP completed PrEP uptake. 
Target: 42% 
Post-intervention: 36% of PrEP eligible patients were prescribed TDF/FTC for PrEP. 
 
 
 
0%
10%
20%
30%
40%
50%
60%
Baseline Post Intervention
Percentage of PreP evaluation completed for 
patients offered PrEP
PreP Evaluation
Completed
0%
5%
10%
15%
20%
25%
30%
35%
40%
Baseline Post Intervention
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Appendix T 
Results of Secondary Outcomes 
1. Clinical staff comprehension of HIV risk identification and screening tool use as 
evidenced by a post-test score of at least 80%: MA1 scored 94%; MA2 scored 56%; and 
Provider 1 scored 75% 
 
 
2. Clinical staff compliance rate for routine HIV PrEP screening tool use of 80% for each 
STI testing, establish new patient, and annual physical exam patient encounter: 53%, 
74%, and 100%, respectively 
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Appendix U 
 
Comparison of PrEP Implementation Cascade for Patients Tested Positive for an STI at Baseline 
and Post-Intervention 
 
*Note: Only one out of five post-intervention patients agreed to initiate PrEP after evaluation; the rest declined PrEP uptake.  
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Appendix V 
Comparison of Patient Population HIV Risk at Baseline and Post-Intervention 
 
*Baseline patient sample over a four-month period of data collection n= 88. Post-Intervention patient sample over a 
three-month period of data collection n=95.  
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